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1. GENERAL INTRODUCTION 
1.1. Female Reproductive Cycle 
The female reproductive system or genital system is a system of sex organs 
within an organism which work together for the purpose of sexual reproduction. The 
female reproductive cycle is the process of producing an ovum and preparmg the 
uterus to receive a fertilized ovum to begin pregnancy. If an ovum is produced but not 
fertilized the reproductive cycle restarts itself through menstruation cycle. The entire 
reproductive cycle takes about 28 days on an average, but may short as 24 days or 
long as 36 days for few women. Under the influence of follicle stimulating hormone 
(FSH) and luteinizing hormone (LH), the ovaries produce a mature ovum in a process 
known as ovulation. In about 14 days of female reproductive cycle, an oocyte reaches 
maturity and release as an owim (Freedman and David, 1992). 
The female internal reproductive organs are the vagina, uterus, fallopian tubes, 
cervix and ovary. The vagina is the place where semen from the male penis is 
deposited into the female's body at the climax of sexual intercourse, a phenomenon 
commonly known as ejaculation. The vagina is a canal that joins the cervix to the 
outside of the body. This is also known as the birth canal. The uterus is a pear-shaped 
muscular organ. Its major function is to accept a fertilized ovum which becomes 
implanted in endometrium and derives nourishment from blood vessels. The fertilized 
ovum becomes an embryo, develops into a foetus and gestates until childbirth. The 
process by which the ovum is released is called ovulation. The external components 
include the mons pubis, pudendal cleft, labia majora, labia minora, Bartholin's glands, 
and clitoris (Figure 1.1.). 
There are two principle ovarian hormone i.e. estrogens, which are capable of 
stimulating female reproductive activity, femaleness and progestogens for the 
pregnancy regulation. If fertilization does not occur the corpus luteum degenerates 
and there is a sudden decrease in vascular supply and tissue is dead. The dead tissue 
with some blood is shed in the process known as menstruation or menstrual cycle 
(Gorbman et al., 1982). Menstrual cycle is the cycle of changes that occurs in the 
uterus and ovary for the purpose of sexual reproduction. Each cycle can be divided 
into three phases based on events in the ovary (ovarian cycle) or in the uterus (uterine 
cycle) (Sherwood and Laurelee, 2013; Silverthom and Unglaub, 2013). The ovarian 
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cycle consist of the follicular phase, ovulation and luteal phase whereas the uterine 
cycle is divided into menstruation, proliferative phase, and secretory phase. Both 
cycles are controlled by the endocrine system and the normal hormonal changes that 
occur can be interfered with using hormonal contraception to prevent reproduction 
(Klumpe/a/.,2013). 
Menstrual cycles are counted from the first day of menstrual bleeding. 
Follicles in the ovary begin to develop under the influence of a complex interplay of 
hormones and after several days one or occasionally two become dominant (non-
dominant follicles atrophy and die). After ovulation, the egg only lives for 24 hrs or 
less without fertilization while the remains of the dominant follicle in the ovary 
become a corpus luteum responsible for producing large amounts of progesterone. 
Under the influence of progesterone, the endometrium (uterine lining) changes to 
prepare for potential implantation of an embryo to establish a pregnancy. If 
implantation does not occur within approximately two weeks, the corpus luteum will 
involute, causing sharp drops in levels of both progesterone and estrogen. The 
hormone drop causes the uterus to shed its lining and egg in a process menstruation 
(Figure 1.2.). A woman's first menstruation is termed menarche and occurs typically 
around age 12-13. The end of a woman's reproductive phase is called the menopause, 
which commonly occurs somewhere between the ages of 45 and 55. 
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Posterior view 
Figure 1.1. Figure shows the different parts of the human female genital tract 
(Source: http://healthfavo.com/female-reproductive-system.html). 
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Figure 1.2. Changing of hormone level during menstrual cycle in female body 
(Source:http://dentistrvandmedicine.blogspot.in/2011/07/menstrualcvclegynecology-
lecture.html). 
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Menstrual cycle is under the control of a range of hormones produced in various parts 
of the female body. 
> Gonadotropin-releasing hormone (GnRH) is produced in the hypothalamus, 
and stimulates body to release follicle stimulating hormone and luteinizing 
hormone. 
> Follicle stimulating hormone (FSH) produced by the pituitary gland, makes 
the eggs in the ovaries to ripen. 
> Luteinizing hormone (LH) stimulates the ovaries to release eggs. 
> Estrogen is produced in the ovaries. It has many roles in female body, 
including the changes in the body during puberty that takes female from girl to 
womanhood. 
> Progesterone is also produced in the ovaries. It works with estrogen to keep 
the reproductive cycle regular and control pregnancy. 
Estrogens have a significant impact on a female's body shape. Its levels are 
significantly higher in women, especially in reproductive age. Besides other 
fianctions, estrogens promote the development of female secondary sexual 
characteristics such as breasts and hips (Hess et al., 1997). The whole process of the 
menstrual cycle starts in the brain after hypothalamus produces GnRH. This hormone 
stimulates pituitary gland which releases FSH. FSH then in the bloodstream 
stimulates the ovaries to start ripening some eggs. FSH also stimulates the ovaries to 
produce estrogen. This encourages the eggs to mature and starts to thicken the lining 
of the uterus so that it is prepared for implantation. 
1.2. History of oral contraceptives 
The Pill (hormonal contraception taken by mouth) fulfilled a dream of 
activists Margaret Sanger and Katherine Dexter McCormick. Over time, the Pill 
helped millions of women to avoid unplanned pregnancies. The birth control pill was 
introduced to the public in the early 1960s. Birth control pills are synthetic hormones 
that mimic the way real estrogen and progestin works in women's body. During the 
1930s, it was discovered that hormones prevents ovulation in rabbits. Frank Colton 
was the inventor of Enovid, the first oral contraceptive pill. Carl Djerassi was the 
inventor of modem oral contraceptives or the pill. Ludwig Haberlandt, an Austrian 
physiologist is known as grandfather of the pill. Indeed, in 1921 he found that rabbits 
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and guinea pigs became temporarily sterile after transplantation of ovaries from 
pregnant animals. These experiments paved the way for pharmacological studies on 
the effect of progesterone on ovulation. The anti-ovulatory effect of progesterone was 
demonstrated by A.W. Makepeace and his co-workers in 1937 by injecting 
progesterone in mated female rabbits. Large-scale experiments with progesterone 
became possible after Russell E. Marker, a professor of organic chemistry found that 
progesterone could be manufactured from a substance named diosgenin, extracted 
from the root of a plant {Dioscorea mexicana) of Mexican jungles (Dhont, 2010). 
The impetus for converting findings of animal experiments into human 
hormonal contraception was given by Margaret Sanger, founder of the Plaimed 
Parenthood Federation of America (PPFA). She approached Pincus in 1951 and 
provided a small grant to begin hormonal contraceptive research. In the same period, 
John Rock, an expert in the treatment of infertility, was experimenting with the oral 
administration of high doses of estrogen (diethylstilboestrol) and progesterone to 
induce pseudo-pregnancy in infertile women. He suggested that high dose of sex 
steroids promotes the growth of the uterus and the fallopian tubes and restored 
fertility but he found that this treatment suppressed ovulation. The biologist Pincus 
and the gynaecologist Rock shared their experiences and their intention to develop a 
hormonal oral contraceptive (Diczfalusy, 1982; Davis, 1978; Speroff, 2009; Gladwell, 
2000). With these two compounds, Rock continued his experiments to induce pseudo-
pregnancy in infertile patients and could prove that ovulation was effectively 
suppressed in all women and that no breakthrough bleeding occurred with a daily 
dose of 10 mg of norethynodrel. This set the stage for the first contraceptive trials in 
woman using norethynodrel as the only compound of the pill. The first pill Enovid 
containing 10 mg of norethynodrel and 150 mg of mestranol. Clinical trials with a 
contraceptive could not be done in the United States because dispensing contraception 
was still a criminal offence at that time. The initial trials therefore were carried out in 
Puerto Rico. In 1957, Food and Drug Administration (FDA) approved the use of 
Enovid 10 mg for the treatment of menstrual disorders and approved it to include as 
contraception in 1960. Enovid containing either 5 mg or 2.5 mg of norethynodrel, 
which in trials had proved to be equally effective, were initially not approved by the 
FDA (Dhont, 2010; Speroff, 2009; Gladwell, 2000; Benagiano etal., 2006). 
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The first oral contraceptive, Enovid was manufactured by G.D. Searle and 
supplied free to clinical trials in Puerto Rico (Figure 1.3.)- It contained 10 mg of 
norethynodrel (a synthetic form of the hormone progesterone) and 0.15 gm of 
synthetic estrogen. Estrogen was a by product of the manufacturing process, but 
removing it caused more breakthrough bleeding. By 1958 the Pill had been tested on 
830 women, mostly in Puerto Rico. Many questions arose due to the ethics of such 
testing, but Puerto Rican women actively sought this new way to control family size. 
In 1960, the FDA announces its approval of Enovid as a birth control pill. Some 100 
million women around the world use the Pill. In early sixties, clinical trials with 
another oral contraceptive containing 4 mg norethisterone and 50 mg ethinylestradiol 
were initiated by the Schering Company (Berlin, Germany) in United Kingdom and 
Belgium. This formula was brought on the market under the name of Anovlar. One 
year later the Organon company, in the Netherlands, followed it with another brand, 
Lyndiol, whose tablets contained 2.5 mg lynestrenol, a 3-desoxo-derivate of 
norethisterone and 75 mg mestranol. Other researchers focused on the effect of 
estrogens on ovulation. Although the mechanism was not fully understood at the time, 
it was clear that estrogens alone also were effective in suppressing ovulation. 
Ethinylestradiol was synthesised in 1938, by Hans Herloff Inhoffen and Walter 
Hohlweg at Schering (Maisel, 1965; Snyder et al., 2001). The natural estradiol is 
poorly absorbed when taken orally and is also quickly inactivated by the liver. 
Substitution at Cn with an ethinyl group results in ethinylestradiol, which is much 
more resistant to degradation. The latter estrogen has subsequently replaced 
mestranol, a 3-methylether which is a pre drug of ethinylestradiol, as the estrogenic 
component of all other contraceptive pills. Several new progestins have emerged over 
the last ten years of which some have been incorporated in novel pill formulas. 
Drospirenone is a spironolactone analogue with anti-mineralocorticoid and moderate 
anti-androgenic effects. Nomegestrol acetate is a 19 norprogesterone derivative which 
binds almost exclusively to the progesterone receptor and therefore is referred to as a 
pure progestational compound (Sitruk-Ware, 2006; Wiegratz and Kuhl, 2006). In 
2010, a new study of 46,000 women conducted over 40 years found that women on 
the pill live longer and are less likely to die prematurely of all causes, including 
cancerandheart disease (Williams and Stancel, 1996). . -
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Figure. 1.3. First oral contraceptive pill "Envoid" 
(Source:http://w\v\v.cleveland.com/healthFit/index.ssf/2010/05/the_birth_control_pill tums_ 
5.html). 
1.2.i. Orai contraceptives 
Oral contraceptives (OCs) are the most popular type of birth control pills. The 
pills stop ovulatiou, preventing the ovaries riorn releasing eggs and they also tliicken 
cervical mucus by making it harder for sperm to enter the uterus (Feminist Women's 
ixk^aiLii x^viiiv^i, ^vv/oy. vyiai v\Jiiiiav^vpii v c- 13 a \^vjiiiuiiiaLiv;ii KJI voi iugwii : ! ciiiva 
progesterone. When taken orally and regularly it acts as the most effective method to 
r»r*=»\/i=>nt nrofTr»or»r*\/ J)r\nV r^arr- ia Pir»r»iio frr*Tn T TQ A f t r c t TMr*n*^ *^ ri=»r1 i n fV»*^  r»linir»al iic«=» 
L^i^ 'vvxj tv L^ t. ^^ ^ A ±*^± xt^ J . i v v ^ ^ i v ^ v^v«i^^xv«^ X xxAVV«u x i v / i x i v^ i^ x^ ». x t x i ^ t ^XV. /AXV^ 'X ^'V« xxi vxx^' vxxx«x^-c«.x VAIJ^^ 
of the pill as contraceptive in 1957. The birth control pill works primarily by blocking 
ovulation. Moreover the pil! also w o^rks bv making cervical mucus thick and 
unreceptive to sperm, slowing down the tubal function and by making the lining of 
the endometrium unreceptive to implantation of a fertilized egg (Kiley and Hamm.ond, 
2007). In general, women do not ovulate until at least 10 days after stopping birth 
vi^iiiicfi p i i i j . i in^ ic a n - iiiaiiuy lv\\j i } j j v j Oi Oiai COiiuaCCpiiVCS. L O n i u m C u Ofai 
contraceptives aiiu Progestui only coiitiaceptives. 
1.2.2. Combined oral contraceptives 
Combined oral contraceptives contain both estrogen and progesterone (Figure 
1.4.). Combined hormonal contraceptives consist of an estrogen and a progestogen 
which act primarily by preventing ovulation through the inhibition of the follicle-
stimulating hormone and luteinizing hormone. The progestogen component also 
renders the cervical mucus relatively impenetrable to spemi and reduces the 
receptivity of endometrium for implantation (lARC, 2007; National Women's Health 
xvesource Centie Inc, 2009). A vaiiety of imiovations have been developed since 
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combined hormonal contraceptives were first available in the late 1950s, including 
changes in drug components, doses used and the temporal sequencing of exposure to 
drugs. These mechanisms render combined hormonal contraceptives very effective in 
the prevention of pregnancy. Annual failure rates vary between 0.02% (two per 
10,000 women/year) when full adherence to instructions for use is assumed (Ketting, 
1988) and 5% for typical use (Fu et ah, 1999). Estrogens are a group of compounds 
named for their importance in both menstrual and estrous reproductive cycles. In 
combined hormonal contraception, ethinylestradiol is the most common estrogen. A 
variety of progestogens are available and these differ in their properties with regard to 
progestogenic and androgenic characteristics. The estrogens and progestogen 
contained in combined hormonal contraceptives are usually given in a monthly cycle. 
In general, estrogen and progestogen are taken in combination for 21 days followed 
by 7 drug-free days (often placebo tablets) during which time withdrawal bleeding 
usually occurs. Other cyclic schedules may be used to reduce or eliminate menses. 
A constant combination of estrogen and progestogen doses may be used 
(monophasic) or the doses of progestogen and (less often) estrogen may vary in two 
(biphasic) or three (triphasic) phases. The most common estrogen in combined 
hormonal contraceptives is ethinylestradiol. Over time, other estrogens have been 
used, including initially mestranol (a pre-drug of ethinylestradiol) and more recently, 
estradiol. In the early development of combined hormonal contraceptives, doses of 
estrogen in the range of 100-150 ^g were commonly used. Contemporary combined 
hormonal contraceptives may be classified by estrogens dose into 'high-dose' (> 50 
|ig), 'moderate-dose' (30-35 jug) and 'low-dose' (15-20 ^g). Three estrogens were 
identified in the late 1920s and 1930s estrone, estriol and estradiol. Currently, they are 
often distinguished as 'first-generation' estranes (such as norethynodrel or 
norethisterone), 'second-generation' gonanes (such as levonorgestrel or 
norgestimate), 'third generation' gonanes (gestodene and desogestrel) and 'fourth-
generation' drospirenone. An additional class of progestogens, the pregnanes (e.g. 
cyproterone and chlormadinone), may also be used. Estranes are highly androgenic, 
while pregnanes and drospirenone have anti-androgenic activity. The later gonanes 
are less androgenic than the earlier compounds in that series (Hammond et al, 2001). 
Progesterones used in OCs are synthetic progesterones, such as norethindrone. 
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norgestrel, norethindrone acetate, ethynodiol diacetate, levonorgestrel, norgestimate. 
desogesirel and drospirenone. 
Ethinyl estradiol Levonorgestrel 
Figure 1.4. Chemical structure of Estrogens and Progesterone 
(Source:http://tmedweb.tulane.edu/pharmwiki/lib/exe/detaii.php/oralcontraceptives2.png?id=c 
ontraceptive pharmacology). 
It is important to recognize that many products are relatively new to the 
market, particularly those that provide newer progestogens. These, together with 
products that are currently under development, create a challenge for the evaluation of 
long-term risk from this class of pharmaceuticals. The vast array of products available 
allows combined hormonal contraception to be tailored to the specific needs and 
preferences of individual women. While some of the newer products may offer 
advantages over the older ones. Some very common products available in India are 
shown in Figure 1.5. (a & b). 
iJS^L 
(a) (b) 
Figure 1.5. Some common brand of combined oral contraceptives pill (a) Mala-D, 
(Source: http://trade.indiamart.com/details.mp?offer=3291188930) (b) Saheli mostly used 
in India (Source: http://www.indiamart.com/hindustan-latex/products.html). 
1.2.3. Progestin only oral contraceptives 
This type of pill contains no estrogen, called the progesteron-only pill, or 
"mini-pill, it's for breastfeeding women because estrogen red 
(National Women's Health Resource Centre Inc, 2009). Figure 1.6. shows 
classification of progestin by which progestin containing pill is manufactured. 
Minipills are slightly less effective thaji regular pills and often cause irregular 
uv;<;3 mux prouuction 
I I (General Intrnrliictinn 
menstrual patterns. Minipills prevents pregnancies mainly by making the cervical 
mucus impermeable to sperm and by making ii more difficult for an egg to attach to 
the uterus lining. Some common minipill brands available in India are shown in 
"IgUXC 1 . / . ( a Ot u ) . 
Classification of Progestins 
Progestins 
Noretliynodiel 19-nor testosterones Spironolactcaie 
C-21 progestins 
Pregnanes 
' DrospiieiToiie 
Estraiies Gonanes 
• Medroxyfffogesteroiie acetate 
• Megestroi acetate 
• CyprotercHie acetate 
• Noretliindroiie • Norgestrel 
• Noretluiidroae acetate • Levonorgesbel 
• Etliyiiodiol diacetate • Noi^estiinate 
• Lynestrenol • Desogestrel 
' Noretliynodrel • Gestodene 
Figure. 1.6. Llassitication of progestins used in making progestin containing only pill 
to u»*„. / / ,, J „ „ — / . . : f : „ i „ / c c n i i /: c\ 
Levonorgesfrel Tablets BP 
UNWANTEI^'72 
Emergency Contraceptive Tablet 
\ 
v . . 
S 
MankmdH^ 
tSC^SK? Mi>:J 
Levonoreestrel ?^ -^ ~ 
Tiil)lels0.75ni2 
(a) (b) 
Figure 1.7. Some common brand of Progestin only oral contraceptives (a) Unwanted 72, (Source: 
http://www.perfectpriceindia.com/price/mankind-unwanted-72-pricc-28039.asp). (b) Levonorgestrel 
(Source: http://ec.princeton.edu/pills/Levonorgestrel.htmn mostly used in India. 
i .Z .4 . ! l i a i «na tu iugn .a i i - iassi in-anui i 
First generation OCs contain high dose (>50 mg) of ethinyl estradiol (EE). 
Second generation OCs contain levonorgestrel, norgestimate, norethindrone fam.ily 
and 30-35 mg EE. Third generation OCs contain desogestrel or gestodene and <30 mg 
EE (Jessica and Lalley, 2000). 
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1.3. Mechanism of action of oral contraceptives 
Combined oral contraceptives are the most widely used oral contraceptives 
that prevent pregnancy mainly by suppressing ovulation. Both progestogen and 
estrogen components suppress luteinizing hormone secretion, which prevents 
ovulation. In addition, progestogen thickens cervical mucus so that sperm cannot 
penetrate the uterus and produces an endometrium that is unreceptive to ovum 
implantation. It may also contribute to contraception by interfering with secretory and 
peristaltic functions inside the fallopian tube (Hatcher et al, 1994). Estrogens and 
progestogens suppress the secretion of follicle-stimulating hormone, which prevents 
the selection and emergence of a dominant follicle. They also minimize breakthrough 
bleeding by stabilizing the endometrium so that irregular shedding is prevented. 
Because the estrogen component potentiates the contraceptive action of the 
progestogen component (probably by increasing the level of intracellular progestogen 
receptors), only a minimal dose of estrogen is needed to maintain the efficacy of the 
combined oral contraceptive (Speroff and Damey, 1996). 
As the progestogens themselves do not always suppress gonadotropins, 
women who take progestin-only oral contraceptives do not always ovulate. The 
contraceptive efficacy of the progestin-only oral contraceptive is therefore dependent 
mostly on its effects on cervical mucus, on the endometrium, and possibly also on the 
fallopian tube (Speroff and Damey, 1996). The progestin-only minipill must be taken 
every day at the same time because its circulating progestogen level is about 75% 
lower than the level resulting from a combination oral contraceptive. Use of the 
minipill may result in irregular menstrual bleeding and the development of functional 
ovarian follicular cysts. Minipills containing levonorgestrel have been associated with 
acne. The acne is caused by the androgenic activity of the unopposed progestogen, 
despite its very low dose, which decreases the level of circulating sex hormone 
binding globulin. As a result, biologically available levels of levonorgestrel and 
testosterone are increased. Low-dose combination oral contraceptives do not produce 
acne because estrogen, which increases sex hormone binding globulin, counteracts the 
effect of progestogen (Speroff and Damey, 1996). The minipill does not significantly 
affect lipid levels, carbohydrate metabolism, or blood coagulation. When it is 
discontinued, fertility retums promptly (Hatcher et al, 1994). 
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Development of new contraceptives for the female depends on a thorough 
knowledge of anatomy and physiology of the reproductive tract. The female have five 
major roles in reproduction: (1) developing a gamete (ovum); (2) receiving the male 
gametes (spermatozoa) and transporting them from the vagina to the distal portion of 
the oviducts; (3) supplying a suitable milieu for fertilization; (4) directing the 
fertilized ovum across the fallopian tubes to the uterine cavity; and (5) providing a 
uterine environment conducive for implantation and maintenance of gestation. These 
functions provide an excellent opportunity for biologic and pharmacologic 
manipulation of the female reproductive process to achieve fertility control (Rivera et 
al., 1999) (Fig. 1.8.). In recent years, much research has been done for the 
identification and possible function of non-steroidal ovarian factors (Adashi, 1992). 
Hypothalamus 
A1t«Tdtian» of 
NSOF 
(OMI. f=S, LI, t 5 ) 
Antlzofia Antkbcdics 
Llgatron 
Sclerosing 
agents 
Plugs 
Alteretlon of 
lubBl 1unc|]on 
hi OCa, P or PGj 
6n HH 
Analogs 
^ E ^ P 
Progestogens 
E ppd/or P 
- Luteolysfs 
(PCs) 
-GnRH 
^ PG Synth ft tass 
Inhibitors 
r-OCs 
P 
•CD 
-Ar>Usp*rm 
AntlbodJfts 
^Cyclic mucus 
Chgngs8 (NFP) 
Figure. 1.8, Figure shows the vulnerable targets for contraception in the female reproductive 
system [GnRH, gonadotropin-releasing hormone; E, estrogen; FS, folliculostatin (inhibin); 
ICD, intracervical device; lUD, intrauterine device; LI, luteinization inhibition factor; LS, 
luteinization stimulation factor; NFP, natural family planning; NSOF, nonsteroidal ovarian 
factor; OC, oral contraceptive; OMI, oocyte maturation mhibitor; P, progestins; PG, 
prostaglandin]. (Source: Moghissi, K and Archer, D, Glob libr. women's med., (ISSN 1756-
2228) 2014). 
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1.4. Scenario in India and abroad 
By the end of the 20* century, oral contraceptives (OCs) had become a feature 
of everyday life, with women reaching for their pill on a daily basis around the globe. 
In United States on June 10, 1957, the Food and Drug Administration (FDA) 
approved Enovid 10 mg (9.85 mg norethynodrel and 150 \ig mestranol) for menstrual 
disorders, based on data from its use by more than 600 women. Numerous additional 
contraceptive trials showed Enovid at 10, 5, and 2.5 mg doses to be highly effective. 
In 1961, G.D. Searle and Co. marketed Enovid 5 mg as an OC (Dhont, 2010). FDA 
refused to consider the application until Searle agreed to withdraw the lower dosage 
forms. On May 9, 1960, the FDA armounced it would approve Enovid 10 mg for 
contraceptive use and did so on June 23, 1960 (Marks, 2001; Junod and Marks, 2002; 
Winter, 1970). The first oral contraceptive introduced outside the United States was 
Schering's Anovlar (norethindrone acetate 4 mg + ethinyl estradiol 50 |ag) on January 
1, 1961 in Australia. The first oral contraceptive introduced in Europe was Schering's 
Anovlar on June 1, 1961 in West Germany (History of Schering, 2008). On December 
28, 1967, the Neuwirth Law legalized contraception in France, including the pill 
(Science Actualities, 2000). The pill is the most popular form of contraception m 
France, especially among young women. It accounts for 60% of the birth control used 
in France. In Japan, Japan Medical Association (JMA) prevented the Pill from being 
approved for nearly 40 years. The Pill was approved in June 1999. According to 
estimates, only 1.3 percent of 28 million Japanese females use the Pill (Dhont, 2010). 
India's national family program has succeeded in lowering the nation's total 
fertility rate to 2.97 from a high of 5.97 in 1950 (United Nations, 2001). The most 
prevalent form of contraception is female sterilization, which accounts for 76% of all 
use among women (Pathak et al, 1998). Research suggests, however, that female 
sterilization is unlikely to contribute to ftirther fertility decline (Pathak et al, 1998; 
Bongaarts and Greenhalgh, 1985). Previous studies have suggested that the general 
concern toward OCs is low due to the social stigma of using contraceptives in an 
unsupportive setting (Lewis, 1986; Janowitz and Bratt, 1996; Bongaarts and Bruce, 
1995; Nag, 1984), lack of knowledge (Basu, 1984; Chaudhury, 2001) desire for more 
children (Athavale and Athavale, 2003; Kumar et al, 1999; Santhya, 2004), the costs 
of acquiring additional information (Pritchett, 1994), worry over possible side effects 
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and fears that reversible methods are ineffective (Bongaarts and Bruce, 1995; 
Athavale and Athavale, 2003; Rajaretnam and Deshpande, 1994; Chaudhury, 2001). 
1.5. Blood serum markers 
1.5.1. Serum Enzymes 
1.5. i . 1. Alkaline phosphatase [EC 3.1.3.1] 
Alkaline phosphatase (ALP, ALKP) is a hydrolase enzyme responsible for 
removing phosphate groups from many types of molecules, including nucleotides, 
proteins, and alkaloids. The process of removing the phosphate group is called 
dephosphorylation (Kim and Wyckoff, 1991). ALP is found in many organs, 
including the placenta, ileal mucosa, kidney, bone, leukocytes, and liver (Lazo et ah, 
2008; Manolio et al., 1992; Bayer et al., 1980; Gordon, 1993; Dufour, 1998; 
McGarrity et al., 1987). In addition to hepatobiliary disease, several additional factors 
can affect ALP serum levels. High-fat food intake can increase AP levels by 30 U/L; 
rise in BMI can increase ALP levels by 25%; tobacco use can lead to 10% rise in ALP 
levels; during the third trimester of pregnancy, ALP levels can increase by 2 to 3 fold 
and oral contraceptives can increase AP levels by 20. Chronic kidney disease has also 
been reported to raise serum levels of the intestinal AP Isoenzyme (Manolio et al, 
1992; Bayer etal., 1980). 
1.5.1.2. Gamma glutamyl transferase [EC 2.3.2.2] 
Gamma-glutamyl transferase or gamma-glutamyl transpeptidase (also y-
glutamyl transferase, GGT) is an enzyme that transfers gamma-glutamyl functional 
groups. It is found in many tissues, the most notable one being the liver, and has 
significance in medicine as a diagnostic marker. GGT catalyzes the transfer of the 
gamma-glutamyl moiety of glutathione to an acceptor that may be an amino acid, a 
peptide or water (forming glutamate) (Tate and Meister, 1985). GGT plays a key role 
in the gamma-glutamyl cycle, a pathway for the synthesis and degradation of 
glutathione and drug and xenobiotic detoxification (Siest et al, 1992).This general 
reaction is: 
(5-L-glutamyl)-peptide + an amino acid peptide ^ 5-L-glutamyl amino acid 
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1.5.1.3. Amino transferases [EC 2.6] 
Aminotransferases or transaminase is an enzyme that catalyzes a type of 
reaction is an enzyme that catalyzes a type of reaction between an amino acid and a-
keto acid. An amino acid contains an amine (NH2) group. A keto acid contains a keto 
(=0) group. In transamination, the NH2 group on one molecule is exchanged with the 
=0 group on the other molecule. The amino acid becomes a keto acid, and the keto 
acid becomes an amino acid (Figure 1.9.). Two important transaminase enzymes are 
AST (SGOT) and ALT (SGPT), the presence of elevated transaminases can be an 
indicator of liver damage (Vroon and Israili, 1990). 
HO HO' 
HO 
Transam inase. 
HO 
N H , 
Figure. 1.9. Aminotransfer reaction between an amino acid and an alpha-keto acid. The 
amino (NH2) group and the keto (=0) group are exchange (Source: 
http://en.wikipedia.0rg/wiki/File:Transaminierung.svg'). 
Aspartate transaminase (AST) or aspartate aminotransferase (EC 2.6.1.1) 
also known as AspAT/ASAT/AAT or serum glutamic oxaloacetic transaminase 
(SGOT), is a pyridoxal phosphate (PLP)-dependent transaminase enzyme. AST 
catalyzes the reversible transfer of an a-amino group between aspartate and glutamate 
and as such, is an important enzyme in amino acid metabolism. AST is found in the 
liver, heart, skeletal muscle, kidneys, brain, and red blood cells and it is commonly 
measured clinically as a marker for liver health. Aspartate transaminase catalyzes the 
interconversion of aspartate and a-ketoglutarate to oxaloacetate and glutamate (Figure 
1.10.) (Kirsch et al, 1984; Berg et ai, 2006). 
Aspartate (Asp) + a-ketoglutarate ^ oxaloacetate + glutamate (Glu) 
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aspartate Q 
transaminase + O' O' 
NH, 
Figure. 1,10. Reaction catalyzed by Aspartate aminotransferase Source: 
(http://en.wikipedia.Org/wiki/File:Aspartate aminotransferase reaction.png) 
Alanine transaminase (EC 2.6.1.2) or ALT is a transaminase enzyme It is also 
called serum glutamic-pyruvic transaminase (SGPT). ALT is found in plasma and in 
various, but is most commonly associated w i^th the liver. It catalyzes the two parts of 
the alanine cycle It catalyzes the transfer of an amino group from L-alanine to a-
ketoglutarate, the products of this reversible transamination reaction being pyruvate 
and L-glutamate (Figure 1.11.) (Aach et al., 1981). 
HOOC 
L-glutamate + pyruvate ?^  a-ketoglutarate + L-alanine 
NH2 H3C—C—COOH ; : 
II 
COOH O 
Alanine 
amino transferase S^  HOOC 
~H "^^  
-NH2 
c—c 
COOH 
\ 
COOH 
Figure. 1.11. Reaction catalyzed by alanine aminotransferase 
(http://en.wikipedia.0rg/wiki/File:Alanine amino transf%C3%A9rase.png). 
(Source: 
1.5.1.4. Lactate dehydrogenase [EC 1.1.1.27] 
Lactate dehydrogenase (LDH) is an enzyme found in animals, plants, and 
prokaryotes. Lactate dehydrogenase is of medical significance because it is found 
extensively in body tissues, such as blood cells and heart muscle. As it is released 
during tissue damage, it is a marker of common injuries and disease. A 
dehydrogenase is an enzyme that transfers a hydride from one molecule to another. 
Lactate dehydrogenase catalyzes the conversion of pyruvate to lactate and back, as it 
converts NADH to NAD^ and back (Figure 1.12.) (Markert, 1984). 
16 
General Introduction 
p>ruva<? 
NADH 
H — O H 
I.-lactate 
LDH 
NAIH 
^ 
OH 
H O 
-NH , 
-n^ 
Figure. 1.12, Mechanism of Lactate dehydrogenase (Source. 
(http://en.wikipedia.org/wiki/File:LDH_mechanism.ipg). 
1.5.2. Lipid profile 
1.5.2.1. Total Cholesterol (TC) 
Cholesterol (C27H46O) a sterol and an essential structural component of animal 
cell membranes that is required to establish proper membrane permeability and 
fluidity. Cholesterol is thus considered within the class of lipid molecules (Figure 
1.13.). In 1769, Francois Poulletier de la Salle was the first who identified cholesterol 
in solid form in gallstones. Cholesterol also serves as a precursor for the biosynthesis 
of steroid hormones, bile acids, and vitamin D (TuUy, 1970; Hanukoglu, 1992). 
Figure 1.13. Cholesterol formation (Source: http://en.wikipedia.org/wiki/File:CholestgLol.svgy 
1.5.2.2: High Density Lipoprotein Cholesterol (HDL-C) 
High-density lipoprotein (HDL) is one of the five major groups of 
lipoproteins, which in order of molecular size, largest to smallest, are chylomicrons, 
very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-
density lipoprotein (LDL) and HDL. Lipoprotein molecules enable the transportation 
of lipids (fats), such as cholesterol, phospholipids and triglycerides within the water 
around cells (extracellular fluid) including the bloodstream. In healthy individuals 
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about 30% of blood cholesterol along with other fats, is carried by HDL (American 
Heart Association, 2009). 
HDL particles remove fats and cholesterol from cells, including within artery 
wall atheroma and transport it back to the liver for excretion or re-utilization, the 
reason why the cholesterol carried within HDL particles (HDL-C) is sometimes called 
"good cholesterol". HDL is the smallest of the lipoprotein particles. Its most abundant 
apolipoproteins are apo A-I and apo A-IL The liver synthesizes these lipoproteins as 
complexes of apolipoproteins and phospholipid which resemble cholesterol-free 
flattened spherical lipoprotein particles; the complexes are capable of picking up 
cholesterol, carried internally, from cells by interaction with the ATP-binding cassette 
transporter A1 (ABCAl). A plasma enzyme called lecithin-cholesterol acyltransferase 
(LCAT) converts the free cholesterol into cholesteryl ester (a more hydrophobic form 
of cholesterol), which is then sequestered into the core of the lipoprotein particle, 
eventually causing the newly synthesized HDL to assume a spherical shape. HDL 
particles increase in size as they circulate through the bloodstream and incorporate 
more cholesterol and phospholipid molecules from cells and other lipoproteins. The 
cholesterol delivered to the liver is excreted into the bile and hence intestine either 
directly or indirectly after conversion into bile acids. Delivery of HDL cholesterol to 
adrenals, ovaries, and testes is important for the synthesis of steroid hormones (Toth, 
2005; Sirtori, 2006). 
1.5.2.3: Low Density Lipoprotein Cholesterol (LDL-C) 
Low-density lipoprotein (LDL) is one of the five major groups of lipoproteins, 
which, in order of molecular size, largest to smallest, are chylomicrons, very low-
density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), LDL and high-
density lipoprotein (HDL). Lipoprotein molecules enable the transportation of lipids 
(fats) such as cholesterol, phospholipids, and triglycerides, within the water around 
cells (extracellular fluid) including the bloodstream. Studies have shown that higher 
levels of type-B LDL particles (as opposed to type-A LDL particles) are associated 
with health problems including cardiovascular disease. LDL molecules are often 
informally called bad cholesterol because they can transport their content of many fat 
molecules into artery walls, attract macrophages, and thus drive atherosclerosis. In 
contrast, HDL molecules are frequently referred to as good cholesterol or healthy 
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cholesterol, because they can remove fat molecules from macrophages in the wall of 
arteries (Dashti et al, 2011). Each native LDL particle enables emulsification, i.e 
surrounding/packaging all fatty acids being carried, enabling these fats to move 
around the body within the water outside cells. Each LDL has a highly hydrophobic 
core consisting of polyunsaturated fatty acid known as linoleate and hundreds to 
thousands (Brunzell et al, 2008). LDL particles contain a variable and changmg 
number of fatty acid molecules, there is a distribution of LDL particle mass and size. 
LDL particles appear harmless until they are within the blood vessel walls and 
oxidized by free radicals it is postulated that ingesting antioxidants and minimizing 
free radical exposure may reduce LDL's contribution to atherosclerosis (Teissedre et 
al, 1996). 
1.5.2.4: Triglycerides (TC) 
Triglyceride (TG or triacylglyceride) is an ester derived from glycerol and three fatty 
acids. As a blood lipid, it enable the bi-directional transference of adipose fat and 
blood glucose from the liver. Saturated compounds are "saturated" with hydrogen all 
available places where hydrogen atoms could be bonded to carbon atoms are 
occupied. Unsaturated compounds have double bonds (C=C) between carbon atoms, 
reducing the number of places where hydrogen atoms can bind to carbon atoms. 
Triglycerides are the main constituents of vegetable oil (typically more unsaturated) 
and animal fats (typically more saturated) (Nelson and Cox, 2000). Triglycerides are a 
major component of human skin oils (Lampe et al., 1983). Triglycerides are formed 
by combining glycerol with three molecules of fatty acid. Alcohols have a hydroxy! 
(H0-) group. Organic acids have a carboxyl (-COOH) group. Alcohols and organic 
acids join to form esters. The glycerol molecule has three hydroxyl (HO-j groups. 
Each fatty acid has a carboxyl group (-COOH). In triglycerides, the hydroxyl groups 
of the glycerol join the carboxyl groups of the fatty acid to form ester bonds: 
HOCH2CH(OH)CH20H + RCOjH + R'COjH + RTO^H 
i 
RC02CH2CH(02CR')CH2C02R"+ 3H2O 
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1.5.3. Genotoxicity tests 
1.5.3.1. Chromosomal aberration, Sister chromatid exchanges, DNA fragmentation 
Chromosome anomalies usually occur when there is an error in cell division 
following meiosis or mitosis. There are many types of chromosome anomalies. They 
can be organized into two basic groups numerical and structural anomalies (National 
Human Genome Research Institute, 2006). The numerical anomilies includes 
aneuploidy (an abnormal number of chromosomes), and occurs when an individual 
either is missing a chromosome from a pair (monosomy) or has more than two 
chromosomes of a pair (trisomy, tetrasomy, etc.). 
The structural anomalies results due to alteration in the structure of 
chromosome for e.g: 
> Deletions: A portion of the chromosome is missing or deleted. 
> Duplications: A portion of the chromosome is duplicated, resulting in extra 
genetic material. 
> Translocations: A portion of one chromosome is transferred to another 
chromosome. There are two main types of translocations: 
• Reciprocal translocation: Segments from two different chromosomes have 
been exchanged. 
• Robertsonian translocation: An entire chromosome has attached to another at 
the centromeres, in humans these only occur with chromosomes 13,14,15,21 
and 22 
> Inversions: A portion of the chromosome has broken off, turned upside down, 
and reattached, therefore the genetic material is inverted. 
> Insertions: A portion of one chromosome has been deleted from its normal 
place and inserted into another chromosome (Paux et al., 2008). 
Sister chromatid exchange (SCE) is the exchange of genetic material between 
two identical sister chromatids. It was first discovered by using the Giemsa staining 
method on one chromatid belonging to the sister chromatid complex before anaphase 
in mitosis. Four to five sister chromatid exchange per chromosome pair, per mitosis is 
in the normal distribution, 14-100 exchanges is not normal and presents a danger to 
the organism (Langlois et at., 1989). 
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DNA fragmentation is the separation or breaking of DNA strands into pieces. 
Spontaneous or accidental DNA fragmentation is fragmentation that gradually 
accumulates in a cell. DNA fragmentation was first observed by Williamson in 1970 
when he observed discrete oligomeric firagments occurring during cell death in 
primary neonatal liver cultures. He described the cytoplasmic DNA isolated from 
mouse liver cells after culture was characterized by DNA fragments with a molecular 
weight consisting of multiples of 135 kDa. This finding was consistent with the 
hypothesis that these DNA fragments were a specific degradation product of nuclear 
DNA. Apoptotic DNA fragmentation is a natural fragmentation that cells perform in 
apoptosis (programmed cell death) (Zhang et al., 2010; Simon et al, 2010). DNA 
fragmentation is a biochemical hallmark of apoptosis. In dying cells, DNA is cleaved 
by an endonuclease that fragments the chromatin into nucleosomal units, which are 
multiples of about 180 bp oligomers and appear as a DNA ladder when run on an 
agarose gel. The enzyme responsible for apoptotic DNA fragmentation is the 
Caspase-activated DNase. CAD is normally inhibited by another protein, the Inhibitor 
of Caspase Activated DNase (ICAD). During apoptosis, the apoptotic effector 
caspase, caspase 3, cleaves ICAD and thus causes CAD to become activated. DNA 
Fragmentation plays an important part in forensics, especially that of DNA profiling 
(Speyerg^a/., 2010). 
1.5.3.2. Comet assay or Single cell gel electrophoresis assay (SCGE) 
Comet Assay or Single Cell Gel Electrophoresis assay (SCGE) is a 
sensitive technique for the detection of DNA damage at the level of the individual 
eukaryotic cell. It was first described by Singh et al., 1988. It has gained popularity as 
a standard technique for evaluation of DNA damage/repair, biomonitoring and 
genotoxicity testing. Cells embedded in agarose on a microscope slide are lysed with 
detergent and high salt to form nucleoids containing supercoiled loops of DNA linked 
to the nuclear matrix. It involves the encapsulation of cells in a low-melting-point 
agarose suspension, lysis of the cells in neutral or alkaline (pH>13) conditions, and 
electrophoresis of the suspended lysed cells. The comet assay is an extremely 
sensitive DNA damage assay (Nandhakumar et al., 2011). This sensitivity needs to be 
handled carefully as it is also vulnerable to physical changes which can affect the 
reproducibility of results. Essentially, anything that can cause DNA damage. This is 
followed by visual analysis with staining of DNA and scoring comets to determine the 
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2.1. Review of literature 
By the early twentieth century, scientists were eager to isolate and wanted to 
determine the formulation and structural properties of synthetic hormones and they 
found that the high doses of these synthetic hormone inhibited ovulation. The 
synthetic progesterone compounds that are used as oral contraceptives are 
norethisterone and norethynodrel. These compounds were first tested in woman in 
1956 in the United States, Puerto Rico and Haiti. The first pill that was launched as an 
oral contraceptive for use contains the combination of nor-19 progestm with a small 
amount of synthetic estrogen as a trade name Enovoid (Junod and Marks, 2002). 
Now-a-days, millions of women of reproductive age around the world use oral 
contraceptives (Burkman, 2001). Over the decades, use of oral contraceptive pills is 
increasing in India (Sharma et al., 2001). In recent years, it is reported that the use of 
oral contraceptive pills by women is increasing as the government and various 
organizations are campaigning for its use in order to avoid pregnancies especially in 
developing countries like Nigeria (Emokpae et al., 2010). According to Bukvic et a! 
oral contraceptives pills are synthesized chemically which can be carcinogenic 
(Bukvic et al., 2000). For avoiding unwanted pregnancy the combined oral 
contraceptives should be taken by users consisting of the steroid hormone estrogens in 
combinafion with a progestogen (lARC, 1979; lARC, WGECRH and WHO, 1987). 
They are currently available in monophasic, biphasic and triphasic preparations, 
depending on the number of different doses of progestogen. Monophasic pills 
maintain a constant dose of estrogens and progestogen, while multiphasic pills allow a 
lower total dose of progestogen to be given by reducing the amount of progestogen 
early in the 20-22 day period of exposure. Progestin-only contraception is an option 
for women that contain only progestin. The most common side-effects of progestin 
only contraception is complication in pregnancy or eccysis and irregularity in 
menstrual cycle (Kaunitz, 1997). Oral contraceptives have been shown abrupt 
increase in the risk of non-fetal myocardial infarction (Ory, 1977; Mann et al.. 1975). 
Both single progestins and combined oral contraceptive shows the genotoxic damage 
and risk of cancers. Study stated that steroids shows genotoxic damage at higher doses 
(Siddique and Afzal 2004a; Siddique et al., 2005a; Siddique et al., 2006a). The 
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therapeutic doses are safe, but care should be taken with regard to their concentration 
as they may be genotoxic in the long term use in humans (Siddique and Afzal, 2005b; 
Siddique et ai, 2007a; Siddique and Afzal, 2008). The International Agency for 
Research on Cancer (lARC) concluded that Progestins (progestogens) are very much 
prone to carcinogenic to humans. This risk is probably due to hormonal steroids, since 
these steroids are very much carcinogenic to humans (Brambilla and Martelli, 2002). 
This review gives a brief account of the studies carried out on the biochemical effects 
and DNA damage of oral contraceptives among users. 
2.2. Biochemical Effects and DNA damage 
Estrogen increases the serum high density lipoprotein cholesterol (HDL-C) 
levels and decrease the levels of low-density lipoprotein cholesterol (LDL-C), where 
as progestogens have a reverse effect i.e., they reduce high-density lipoprotein 
cholesterol (HDL-C) and raise low-density lipoprotein cholesterol (LDL-C) levels. 
The lipoprotein profile resulting from the use of oral contraceptive is therefore, 
dependent on the balance between the potencies of the estrogen and progestogen 
components. Although, the high-dose progestogens contained in the older oral 
contraceptives did raise low-density lipoprotein cholesterol (LDL-C) and reduce high 
density lipoprotein cholesterol level (HDL-C), modem low-dose progestogens do not 
appear to affect the lipid profile in users. The increased risk of cardiovascular disease 
in oral contraceptive users is due to venous or arterial thrombosis (Speroff and 
Damey, 1996; Brerman et al., 1997). 
Several authors have observed that the use of oral contraceptive pills (OCPs) 
may increase the risk of cardiovascular disease by increasing the levels of 
triglycerides (WHO, 1995), but the position over the cholesterol is not clear. Wynn et 
al. (1966) have reported a significant difference in cholesterol levels in young women 
using OCPs. Other authors observed a significant increase in all lipid fractions in 
women using OCPs (Donde and Virkar, 1975). Another study showed that serum total 
cholesterol levels were higher among oral contraceptive users. There was an increase 
in total cholesterol due to the increased in P-lipoprotein cholesterol. A decrease in a-
lipoprotein cholesterol and an increase in triglycerides were also observed (Webber et 
al., 1982). OC users experienced an increase in the levels of triglycerides, total 
cholesterol, VLDL, and HDL that were greater than those experienced by non-
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hormonal contraceptive users (Berenson et ah, 2009). One of the long-range potential 
concerns with the use of oral contraceptive agents (OCA) is the increase in serum 
lipids. A study carried out on Nigerian oral contraceptive users revealing the level of 
serum cholesterol was significantly higher compared to controls. The elevation of 
serum cholesterol levels may be due to the estrogen content in oral contraceptives. In 
conclusion, this study has demonstrated the need to periodically reassess the 
biochemical parameters of oral contraceptive users, especially those who have been 
on the steroids for a long time. This is necessary in view of significant biochemical 
changes such as increase of total protein, albumin and cholesterol levels (Obisesan et 
ai, 2002). Another study on biochemical changes on oral contraceptive have shown 
the higher levels of triglycerides, total cholesterol, LDL-cholesterol and VLDL-
cholesterol in OCs users women. The increase in OCP triglycerides is due to the 
increase in the synthesis. OCP intake produce changes in lipid metabolism in women, 
but such changes may not necessarily lead to pathogenic concentration resulting in a 
cardiovascular disease with the prolonged use of not more than 4 years (Emokpae et 
al., 2010). Since, the effects caused by OCP intake are short lived, it could be said 
that the effects of these hormonal preparations may be physiologic rather than 
pathogenic (Karam, 2001). Many studies have analyzed the relation between 
cardiovascular risk factors and oral contraceptive use in adult women. Elevated blood 
levels of lipids are probably the most important biochemical risk factor for 
atherosclerosis. In the liver, triglycerides synthesis is enhanced by estrogen and 
inhibited by androgen and these triglycerides are partly brought into the circulation as 
low-density lipoproteins. In another study, it was observed that in adolescent girls 
serum total cholesterol was significantly higher among oral contraceptive users 
compared to non-users (Nawrot et al., 2003). 
The effects of oral contraceptive agents (OCAs) on lipid metabolism were 
reviewed recently by Beck in 1973 who points out that the estrogen-induced rise in 
serum triglyceride levels is dose regulated and is similar to the general increase in 
serum triglycerides found in postmenopausal women. Oral Contraceptives have been 
reported to affect all serum lipids, but their effect on the triglycerides and VLDL is 
most consistent and striking (Gereshberg et al., 1968; Molitch et al., 1974). Some data 
also showed a small, non significant inverse relationship between OC users and HDL 
cholesterol. A recent report showed that different OC preparations had varying effects 
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on HDL cholesterol. HDL cholesterol levels appeared to be directly related to 
estrogen dose and inversely related to progestin dose (Bradley et al., 1978). 
Progestins (progestogens) have been classified by the International Agency for 
Research on Cancer (lARC) as possibly carcinogenic to humans on the basis of 
sufficient or limited evidence for carcinogenicity in experimental animals and 
inadequate evidence for carcinogenicity in humans (Bauman et al, 1973; Peters et al, 
1986; Schwarz and Weiss, 1986; Chilvers et al, 1987).The higher rate of cellular 
genetic damage in terms of increased frequencies of SCEs and chromosome 
aberrations have been reported in women during pregnancy (Imao, 1983; Tanigawa, 
1989). The studies on the mutagenic effects of OC drugs are limited. Studies on 
cultured lymphocytes derived from contraceptive users have demonstrated both 
positive and negative outcomes in terms of genotoxic effects. However, these 
contradictory results date back to the 1970's (McQuarrie et al, 1970; Bishun et al, 
1972; Shapiro et al, 1972) and more recent studies show that estrogens induce the 
formation of endogenous DNA adducts both in humans and animals and suggest that 
these could ultimately lead to cancer development (Hundal et al, 1997; Dhillon and 
Dhillon, 1994; Liehr, 1990). Studies carried out on biochemical and DNA damaging 
effects of oral contraceptives is shown in Table 2.1. 
2.3. Conclusion 
The studies performed on oral contraceptive users clearly shows the marked 
effects on enzymes, carbohydrates and serum lipids. High level of serum lipid invites 
many problems among contraceptive users i.e. cardiovascular risk by increasing in the 
cholesterol level, but the full impact of oral contraceptive on cardiovascular risk 
factors may not be fully concluded from short duration studies done so far. The 
duration of using oral contraceptives also have importance in studying the effects 
among women. 
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2.1. Review of literature 
By the early twentieth century, scientists were eager to isolate and wanted to 
determine the formulation and structural properties of synthetic hormones and they 
found that the high doses of these synthetic hormone inhibited ovulation. The 
synthetic progesterone compounds that are used as oral contraceptives are 
norethisterone and norethynodrel. These compounds were first tested in woman in 
1956 in the United States, Puerto Rico and Haiti. The first pill that was launched as an 
oral contraceptive for use contains the combination of nor-19 progestin with a small 
amount of synthetic estrogen as a trade name Enovoid (Junod and Marks. 2002). 
Now-a-days, millions of women of reproductive age around the world use oral 
contraceptives (Burkman, 2001). Over the decades, use of oral contraceptive pills is 
increasing in India (Sharma et al., 2001). In recent years, it is reported that the use of 
oral contraceptive pills by women is increasing as the government and various 
organizations are campaigning for its use in order to avoid pregnancies especially in 
developing countries like Nigeria (Emokpae et al., 2010). According to Bukvic et al 
oral contraceptives pills are synthesized chemically which can be carcinogenic 
(Bukvic et al., 2000). For avoiding unwanted pregnancy the combined oral 
contraceptives should be taken by users consisting of the steroid hormone estrogens in 
combination with a progestogen (lARC, 1979; lARC, WGECRH and WHO, 1987). 
They are currently available in monophasic, biphasic and triphasic preparations, 
depending on the number of different doses of progestogen. Monophasic pills 
maintain a constant dose of estrogens and progestogen, while multiphasic pills allow a 
lower total dose of progestogen to be given by reducing the amount of progestogen 
early in the 20-22 day period of exposure. Progestin-only contraception is an option 
for women that contain only progestin. The most common side-effects of progestin 
only contraception is complication in pregnancy or eccysis and irregularity in 
menstrual cycle (Kaunitz, 1997). Oral contraceptives have been shown abrupt 
increase in the risk of non-fetal myocardial infarction (Ory, 1977; Mann et al., 1975). 
Both single progestins and combined oral contraceptive shows the genotoxic damage 
and risk of cancers. Study stated that steroids shows genotoxic damage at higher doses 
(Siddique and Afzal 2004a; Siddique et al, 2005a; Siddique et al, 2006a). The 
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therapeutic doses are safe, but care should be taken with regard to their concentration 
as they may be genotoxic in the long term use in humans (Siddique and Afzal, 2005b; 
Siddique et al., 2007a; Siddique and Afzal, 2008). The International Agency for 
Research on Cancer (lARC) concluded that Progestins (progestogens) are very much 
prone to carcinogenic to humans. This risk is probably due to hormonal steroids, since 
these steroids are very much carcinogenic to humans (Brambilla and Martelli, 2002). 
This review gives a brief account of the studies carried out on the biochemical effects 
and DNA damage of oral contraceptives among users. 
2.2. Biochemical Effects and DNA damage 
Estrogen increases the serum high density lipoprotein cholesterol (HDL-C) 
levels and decrease the levels of low-density lipoprotein cholesterol (LDL-C), where 
as progestogens have a reverse effect i.e., they reduce high-density lipoprotein 
cholesterol (HDL-C) and raise low-density lipoprotein cholesterol (LDL-C) levels. 
The lipoprotein profile resulting from the use of oral contraceptive is therefore, 
dependent on the balance between the potencies of the estrogen and progestogen 
components. Although, the high-dose progestogens contained in the older oral 
contraceptives did raise low-density lipoprotein cholesterol (LDL-C) and reduce high 
density lipoprotein cholesterol level (HDL-C), modem low-dose progestogens do not 
appear to affect the lipid profile in users. The increased risk of cardiovascular disease 
in oral contraceptive users is due to venous or arterial thrombosis (Speroff and 
Damey, 1996; Brerman etal., 1997). 
Several authors have observed that the use of oral contraceptive pills (OCPs) 
may increase the risk of cardiovascular disease by increasing the levels of 
triglycerides (WHO, 1995), but the position over the cholesterol is not clear. Wynn et 
al. (1966) have reported a significant difference in cholesterol levels in young women 
using OCPs. Other authors observed a significant increase in all lipid fractions in 
women using OCPs (Donde and Virkar, 1975). Another study showed that serum total 
cholesterol levels were higher among oral contraceptive users. There was an increase 
in total cholesterol due to the increased in P-lipoprotein cholesterol. A decrease in a-
lipoprotein cholesterol and an increase in triglycerides were also observed (Webber et 
al., 1982). OC users experienced an increase in the levels of triglycerides, total 
cholesterol, VLDL, and HDL that were greater than those experienced by non-
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hormonal contraceptive users (Berenson et al, 2009). One of the long-range potential 
concerns with the use of oral contraceptive agents (OCA) is the increase in serum 
lipids. A study carried out on Nigerian oral contraceptive users revealing the level of 
serum cholesterol was significantly higher compared to controls. The elevation of 
serum cholesterol levels may be due to the estrogen content in oral contraceptives. In 
conclusion, this study has demonstrated the need to periodically reassess the 
biochemical parameters of oral contraceptive users, especially those who have been 
on the steroids for a long time. This is necessary in view of significant biochemical 
changes such as increase of total protein, albumin and cholesterol levels (Obisesan et 
al, 2002). Another study on biochemical changes on oral contraceptive have shown 
the higher levels of triglycerides, total cholesterol, LDL-cholesterol and VLDL-
cholesterol in OCs users women. The increase in OCP triglycerides is due to the 
increase in the synthesis. OCP intake produce changes in lipid metabolism in women, 
but such changes may not necessarily lead to pathogenic concentration resulting in a 
cardiovascular disease with the prolonged use of not more than 4 years (Emokpae et 
al., 2010). Since, the effects caused by OCP intake are short lived, it could be said 
that the effects of these hormonal preparations may be physiologic rather than 
pathogenic (Karam, 2001). Many studies have analyzed the relation between 
cardiovascular risk factors and oral contraceptive use in adult women. Elevated blood 
levels of lipids are probably the most important biochemical risk factor for 
atherosclerosis. In the liver, triglycerides synthesis is enhanced by estrogen and 
inhibited by androgen and these triglycerides are partly brought into the circulation as 
low-density lipoproteins. In another study, it was observed that in adolescent girls 
serum total cholesterol was significantly higher among oral contraceptive users 
compared to non-users (Nawrot et ah, 2003). 
The effects of oral contraceptive agents (OCAs) on lipid metabolism were 
reviewed recently by Beck in 1973 who points out that the estrogen-induced rise in 
serum triglyceride levels is dose regulated and is similar to the general increase in 
serum triglycerides found in postmenopausal women. Oral Contraceptives have been 
reported to affect all serum lipids, but their effect on the triglycerides and VLDL is 
most consistent and striking (Gereshberg et al, 1968; Molitch et al, 1974). Some data 
also showed a small, non significant inverse relationship between OC users and HDL 
cholesterol. A recent report showed that different OC preparations had varying effects 
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on HDL cholesterol. HDL cholesterol levels appeared to be directly related to 
estrogen dose and inversely related to progestin dose (Bradley et al., 1978). 
Progestins (progestogens) have been classified by the International Agency for 
Research on Cancer (lARC) as possibly carcinogenic to humans on the basis of 
sufficient or limited evidence for carcinogenicity in experimental animals and 
inadequate evidence for carcinogenicity in humans (Bauman et al., 1973; Peters et al., 
1986; Schwarz and Weiss, 1986; Chilvers et al., 1987).The higher rate of cellular 
genetic damage in terms of increased frequencies of SCEs and chromosome 
aberrations have been reported in women during pregnancy (Imao, 1983; Tanigawa, 
1989). The studies on the mutagenic effects of OC drugs are limited. Studies on 
cultured lymphocytes derived from contraceptive users have demonstrated both 
positive and negative outcomes in terms of genotoxic effects. However, these 
contradictory results date back to the 1970's (McQuarrie et al., 1970; Bishun et al, 
1972; Shapiro et al., 1972) and more recent studies show that estrogens induce the 
formation of endogenous DNA adducts both in humans and animals and suggest that 
these could ultimately lead to cancer development (Hundal et ah, 1997; Dhillon and 
Dhillon, 1994; Liehr, 1990). Studies carried out on biochemical and DNA damaging 
effects of oral contraceptives is shown in Table 2.1. 
2.3. Conclusion 
The studies performed on oral contraceptive users clearly shows the marked 
effects on enzymes, carbohydrates and serum lipids. High level of serum lipid invites 
many problems among contraceptive users i.e. cardiovascular risk by increasing in the 
cholesterol level, but the full impact of oral contraceptive on cardiovascular risk 
factors may not be fully concluded from short duration studies done so far. The 
duration of using oral contraceptives also have importance in studying the effects 
among women. 
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Table-2.1 Studies carried out on biochemical and DNA damaging effects of oral contraceptives. 
S.No. 
1. 
2. 
3. 
4, 
5. 
6. 
7. 
Oral Contraceptive 
Estrogen containing oral 
contraceptive 
Oral pill (Triphasic OC), 
Vaginal ring (Nuva 
ring) 
Transdermal patch 
(Ortho Evra) 
Injectable (DMPA-
depot medroxy 
}jr>jgv,Sn..ruiiv 
acetate),Oral pill-
ethinyl estradiol and 
Oral contraceptives 
Low dose 
contraceptives 
(erhinyiesrradiol) 
combined with 
progestin component 
dienogest or 
drospirenon 
Biphasic lofeminal 
tablets (norgestrel + 
ethinyl estradioi) 
Ethinyl estradiol and 
progestin 
Parameter Studied 
Blood pressure and 
serum lipids 
Lipid soluble 
antioxidant and Serum 
levels of enzyme 
Serum lipids 
Serum protein and 
cholesterol 
Effect on deep venous 
thrombosis and 
arterial by iipid 
abnormalities 
Serum lipids and 
blood pressure 
Blood pressure and 
serum total lipids 
Conclusion 
Higher level of 
serum lipid and 
lower blood 
pressure 
Low lipid serum 
level, decrease 
coenzyme BK, 
and total anti-
oxidant capacity 
assay 
Elevate lipid 
level in oral pill 
users and low 
HDL and high 
LDL level in 
Higher serum 
protein, 
increased 
cholesterol 
levels 
Deep venous 
thrombosis in 
users (aneriai 
thrombosis 
increases) 
Total lipid 
increases 
reduced blood 
pressure level 
Higher systolic 
blood pressure 
and higiicf level 
of serum total 
Author 
Webber et al.. 
(1982) 
Pa Ian etai. 
(2010) 
Berenson et 
al., (2009) 
Obisesan et 
al., (2002) 
Tzankova et 
a/., (2010) 
Emokpae et 
a/., (2010) 
Nawrot et al., 
(2003) 
lipids 
8. Low dose oral 
contraceptive (ethinyl 
estradiol/gestodene) 
Lipid level and blood Normal level of Giribela et al., 
pressure lipids, normal (2007) 
Utr 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
Monophasic pills (ethinyl 
estradiol) 
Combined oral 
contraceptive (estrogen 
ethinyl estradiol + 
progestogen) 
Lyndiol pill (lynoestrenol 
and progestin) 
Oral contraceptive agents 
combination type 
(Progestogen + Estrogen) 
Norinyl (1 mgof 
norethindrone + 80 ng of 
mestranol) 
Oral contraceptive 
Oral contraceptive pill 
(norethindrone + mestranol) 
Contraceptive pill 
(levenorgestrel + ethinyl 
estradiol) 
Contraceptive pill 
Norethindrone, 
OrthoNovum (1/35 and777) 
ethinodiol diacetate 
Blood sample (Total 
plasma Cortisol was 
measured with a 
radioimmunoassay), 
and first saliva sample 
(Basal free Cortisol 
level) 
Serum lipids and 
lipoproteins 
SGOT levels (serum 
glutamic oxaloacetic 
transaminase) 
Concentration of 
plasma ascorbic acid 
in leukocytes 
Vitamin level and 
lipid levels in serum 
Serum lipids 
Serum lipids 
Serum lipids 
Plasma vitamins (A, 
E, C) plasma 
triglycerides and 
cholesterol, 
leukocytes 
Lipoproteins and 
Serum lipids 
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Basal free 
Cortisol level 
increases, No 
effect on 
Cortisol level 
Serum lipids is 
higher 
Increase in 
SGOT (serum 
glutamic 
oxaloacetic 
transaminase) 
Decrease plasma 
ascorbic acid 
Decrease in 
serum vitamin B 
12, Lipid level 
in serum higher 
Increase level of 
serum lipids 
Higher levels of 
total lipids 
Decrease serum 
lipids 
Increase level of 
vitamin, plasma 
triglycerides, 
cholesterol, 
leukocytes that 
makes the risk 
of myocardial 
infraction 
Higher 
lipoprotein, high 
Serum lipids 
Kirschbaum et 
a/., (1999) 
Abdel Barry et 
a/., (2011) 
Stoll,(1967) 
McLeroy and 
Schendel, 
(1973) 
Smith et al., 
(1975) 
Kannel,(1979) 
Hennekens et 
a/., (1979) 
Demacker et 
a/., (1982) 
Yeung, (1976) 
Walsh and 
Sacks, (1993) 
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19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
Combined oral contraceptive 
estrogen + progestin 
(desogestrel, ievonorgestrel and 
norethisterone) 
Combined pills (ethinyl 
estradiol) 
Oral contraceptive pill 
Ievonorgestrel (90 ^g) 
Ethinyl estradiol (20 \ig) 
Monophasic oral contraceptive 
(Ievonorgestrel (100 ]ig) + 
ethinylestradiol 20 \ig) 
Ortho Nuvum 7/7/7, Triphasil 
(combination of norethindrone, 
ethinyl estradiol) 
Cyproterone acetate + ethinyl 
estradiol, Desogestrel + ethinyl 
estradiol 
Mifepristone (contraceptive 
pill) 
Ethinyl estradiol and 
Histopathology 
Bone markers, serum 
biochemistry. Bone 
mineral measurement 
Serum levels of lipid-
soluble antioxidants 
Demographic data 
Follicle diameters and 
serum progesterone 
and 17p-estradiol 
Serum concentration 
of ethinyl estradiol by 
Radioimmunoassay 
Lipid metabolism 
phosphatase, hirsutism 
of adolescents with 
polycystic ovary 
syndrome (PCOS) 
Biochemical 
parameter (serum 
alkaline phosphatase 
and serum glutamyl 
pyruvate 
transaminase) 
Assessment of ovarian 
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Risk of 
endometrial 
cancer is 
decreased 
Decreased bone 
formation; 
serum albumin 
is lower in oral 
contraceptive 
users. Normal 
bone mineral 
Lower level of 
serum levels of 
lipid soluble 
antioxidants 
Use of this 
composition 
does not delay 
the return to 
fertility 
Suppression of 
ovarian activity 
in users 
Serum 
concentration of 
ethinyl estradiol 
increases 
Lipid 
metabolism 
increased, 
decrease 
hirsutism 
Increase 
biochemical 
parameters 
(serum alkaline 
phosphatase and 
serum glutamyl 
pyruvate 
transaminase) 
Inhibition of 
Weiderpass ei 
a/., (1999) 
Garnero el al., 
(1995) 
Palan ei al., 
(2006) 
Bamhart et a/., 
(2009) 
Coney and 
DelConte, 
(1999) 
Sinofsky and 
Pasquale, 
(1998) 
Mastorakos et 
al., (2002) 
Agarwal etal., 
(2009) 
Spona et al.. 
29 
28. 
29. 
30. 
31. 
32. 
33. 
chlormadinone acetate 
Depot medroxyprogesterone 
Oral contraceptive pill (20 |j,g) 
Oral contraceptive (ethinyl 
estradiol + norgestimate), 
Contraceptive patch (ethinyl 
estradiol + norelgestromin) 
Ethinyl estradiol + progestin 
Oral contraceptive (estrogen), 
DMPA (progestin) 
Oral contraceptive (30 \ig 
ethinyl estradiol + 2 mg 
dienogest) 
Mircette (desogestrel / ethinyl 
estradiol) 
function, thickness of 
endometrium, cervical 
reaction sex, hormone 
level and overall 
tolerability 
Menstrual symptoms 
and Physiologic 
symptoms 
Body Mass Index 
(BMI) and serum 
androgen levels 
Pelvic pain, bleeding. 
headaches, breast 
tenderness 
Demographic data 
form, serum 
testosterone and 
estradiol level 
Survey based Study 
Serum lipids. 
carbohydrate 
metabolism, endocrine 
parameters 
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ovulation and 
unfavorable 
condition for 
fertilization. 
pregnancy 
No adverse 
effects 
The 
contraceptive 
patch had an 
effect 
comparable, to 
the OC on 
several key 
androgenic 
potential as a 
therapeutic 
agent for 
disorders of 
androgen excess 
Pelvic pain. 
bleeding and 
breast 
tenderness 
shown, 
headaches 
problem 
Oral 
contraceptives 
have low level 
of testosterone 
compared to 
DMPA and high 
level of estradiol 
Slight delay in 
regaining 
fertility after the 
use of this oral 
contraceptive 
Increase serum 
lipids, no 
changes in 
carbohydrate 
metabolism, 
effect on 
(2010) 
Berenson et 
al., (2008) 
White et al. 
(2005) 
Sulak et al.. 
(2000) 
Schaffir e/a/.. 
(2010) 
Wiegratz and 
Kuhl, (2006) 
Berga,(1998) 
30 
34. 
35. 
36. 
37. 
38. 
39. 
Oral contraceptive pill 
Oral contraceptive pill 
Monophasic combined oral 
contraceptive contain 0.3 mg 
norgestrel+0.03 ethinyl 
estradiol 
Levonorgestrel with ethinyl 
estradiol 
Levonorgestrel in low (150 ^g, 
high (250 |ig) and triphasic 
(50-125 ng) doses, 
Norethindrone in low (500 ng), 
high (1000 |ig) and triphasic 
(500-1000 ^g) and desogestrel 
(150 ng) with 30-40 \ig ethinyl 
estradiol 
Oral contraceptive pills 
Standard 
questionnaire was 
used to record 
descriptive 
characteristics and 
medical and 
reproductive history 
Total serum 
cholesterol, high-
density lipoprotein 
cholesterol. 
Triglycerides and 
LDL-cholesterol 
Total serum 
cholesterol, 
triglycerides, LDL 
cholesterol and Very 
low density 
lipoproteins (VLDL) 
Total cholesterol, 
high-density 
lipoprotein 
cholesterol, high-
density lipoprotein 
subfraction 2, and 
apolipoprotein A-I 
concentrations 
Serum total 
cholesterol and 
triglycerides 
Total cholesterol, 
LDL-cholesterol and 
triacylglycerol 
concentrations 
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endocrine 
parameter 
Liver carcinoma 
found in oral 
contraceptive 
users 
Total serum 
cholesterol and 
LDL-cholesterol 
level increased 
and HDL level 
decreased 
Total serum 
cholesterol, 
triglycerides, 
LDL cholesterol 
increased 
Changes found 
in the lipid 
profile 
Progestins may 
have unwanted 
metabolic side 
effects when 
combined with 
estrogen 
Different 
types of OC 
may have 
different 
impacts on 
blood analytes 
due to variable 
estrogen and 
progestogen 
Palmer et al.. 
(1989) 
Yesmin ei ai., 
(2013) 
Mohammad ei 
a/., (2013) 
Young and 
DelConte, 
(1999) 
Godsland et 
a/., (1990) 
Thane et al., 
(2002) 
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content 
40. Estrogen-dominant oral 
contraceptives (Ortho Novum 
1-35, Ortho 
Novum 777, Desogen, 
orModicon) containing 0.035 
mg ethinyl estradiol. 
Triglycerides Total 
triglycerides 
were 
significantly 
higher in the 
users compared 
to the nonusers 
Khoo et al., 
(1999) 
41. Ethinyl estradiol and 
drospirenone 
LDL cholesterol, 
HDL cholesterol 
No negative 
effects were 
found 
Machado et 
a/., (2010) 
42. Ovral (75 ^g norgestrel and 7.5 Total serum 
|xg ethinyl estradiol); Demulen 
(150 \ig ethynodiol diacetate 
and 7.5 ng ethinyl estradiol) 
cholesterol, 
triglycerides, HDL 
cholesterol and low 
density lipoproteins 
(LDL) 
Oral 
contraceptive 
treatment was 
associated with 
an increase in 
plasma 
triglycerides 
(TG) and a 
decrease in low 
density 
lipoproteins 
(LDL) size 
Parks et al., 
(1989) 
43. Oral Contraceptives (Estrogens 
and Progestins) 
High-density-
lipoprotein cholesterol 
Level varied 
with the type 
and dose of the 
component 
steroids, in 
general 
increasing with 
increasing dose 
of estrogen and 
decreasing with 
increasing dose 
or potency of 
progestin 
Bradley et al.. 
(1978) 
44. Estrogen/Progestin Low-density and high-
density lipoproteins 
Oral 
contraceptives 
that are high in 
estrogen and 
low in progestin 
(Enovid or 
Oracon) had 
significantly 
higher 
concentrations 
of high density 
Wahl et al., 
(1983) 
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45. 
46. 
47 
48. 
49. 
50. 
Oral contraceptives 
A transdermal patch delivering 
0.025 mg estradiol and 0.125 
mg norethisterone acetate 
Norethisterone 1 mg/ethinyl 
estradiol 35 ^g (NET/EE) or 
levonorgestrel 150 jAg/ethinyl 
estradiol 30 ng (LNG/EE) 
Oral contraceptives 
Oral Contraceptive 
Oral contraceptives 
Total cholesterol, 
triglycerides, high-
density lipoprotein 
cholesterol and 
apolipoprotein 
Total cholesterol, 
VLDL cholesterol and 
LDL cholesterol 
HDL and LDL 
cholesterol and 
alkaline phosphatase. 
bilirubin and aspartate 
transaminase (SGOT) 
Serum Triglyceride 
levels and 
cholesterol levels 
Alkaline phosphatase. 
SGOT, SGPT 
High-density 
lipoprotein, Low-
density 
lipoprotein, 
Triglycerides, 
Alkaline 
phosphatase. 
Aspartate 
aminotransferase. 
Alanine 
aminotransferase. 
lipoprotein 
cholesterol as 
compared to 
non-users 
Increased high-
density 
lipoprotein 
cholesterol and 
decreased low-
density 
lipoprotein 
cholesterol were 
also observed 
No Effect 
HDL and LDL 
cholesterol is 
reduced and 
alkaline 
phosphatase, 
bilirubin and 
aspartate 
transaminase 
(SGOT) are 
suppressed 
No Effects 
Slightly raised 
alkaline 
phosphatase 
value and high 
transaminase 
levels 
Increase in High-
density 
lipoprotein, low-
density 
lipoprotein. 
Triglycerides, 
Aspartate 
aminotransferase. 
Alanine 
aminotransferase. 
Y Glutamyl 
Vaziri et aL, 
(1993) 
Brynhildsen 
and Hammar, 
(2002) 
Loke et aL, 
(1992) 
Wynn et al.. 
(1966) 
Thulin and 
Nermark, 
(1966) 
Campesi et aL, 
(2012) 
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51. 
52 
53. 
54. 
55. 
Oral contraceptives 
Oral contraceptives 
150 i^g desogesterel and 30 ng 
ethinyl estradiol, 250 jug 
Norgestamine and 35 |ig 
ethinyl estradiol, 75ng 
gestodene and 30 i^g ethinyl 
estradiol. 
150 ng desogestrel and 20 or 
30 ng ethinylestradiol 
20, 40 and 75 |ag/ml for 
norethindrone and 10, 25 and 
50 fig/ml for norgestrel) 
y Glutamyl 
transpeptidase 
Alkaline phosphatase, 
SCOT, SGPT and 
serum albumin and 
globulin 
Alkaline phosphatase, 
and serum 
triglycerides albumin 
and globulin y 
Glutamyl 
transpeptidase 
Chromosomal 
aberration, sister 
chromatid exchanges 
Sister chromatid 
exchanges, Comet 
assay 
Sister chromatid 
exchanges, 
Chromosomal 
aberrations 
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transpeptidase 
and decreased in 
alkaline 
Phosphatase 
decreased 
Multiple 
changes in 
serum levels do 
not necessary 
indicate liver 
damage 
y Glutamyl 
transpeptidase 
increased and 
Alkaline 
phosphatase, 
serum 
triglycerides, 
albumin 
globulin 
decreased 
Frequency of 
cells with 
aberrations 
found, 
chromatid gaps 
and breaks were 
predominantly 
observed 
OC users 
showed 
significantly 
higher 
damage by both 
cytogenetic 
methodologies 
compared with 
untreated 
control women 
The use of 
norgestrel is 
associated with 
a significant 
increase in the 
incidence of 
chromosomal 
abnormalities 
Shaaban et al.. 
(1982) 
Schiele et al.. 
(1998) 
Mahrous, 
(2008) 
Biri et al.. 
(2002) 
Ahmad et al.. 
(2001) 
34 
56. 
57. 
58. 
59. 
60. 
Lyndiol 2.5 
Estrogen and 
medroxyprogesterone acetate 
and IVP-estradiol only 
Norethynodrel 
Norgestrel 
Oral contraceptive 
Chromosome 
abnormalities 
Sister-chromatid 
exchange 
Chromosomal 
aberrations and sister 
chromatid exchanges 
Chromosomal 
aberration and sister 
chromatid exchanges 
Chromosomal 
aberration analysis, 
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per cell as well 
as with an 
increase in the 
number of 
abnormal cells 
Lyndiol 2.5 may 
have a slight 
anti-mitotic 
effect but do not 
provide any 
evidence of 
steroids causing 
structural 
chromosomal 
abnormalities 
SCE frequencies 
were 
significantly 
elevated 
during the third 
month 
An ascorbic acid 
potent enough to 
reduced the 
genotoxic 
damage of 
norethynodrel in 
the presence of 
metabolic 
activation 
and may reduce 
the possible risk 
of 
carcinogenesis 
Treatment of 
peripheral blood 
lymphocytes 
with vitamins C 
or E, either 
separately or in 
combination, 
decreases the 
genotoxic 
damage caused 
by norgestrel 
Gaps and breaks 
of chromosome 
Timson. 
(1969) 
Kayikciogiu et 
ai,(2000) 
Siddique et al.. 
(2007a) 
Siddique et al.. 
(2007b) 
Naz et ai. 
(2012a) 
35 
61. 
62. 
63. 
17 a Ethynylestradiol and 
Norgestrel 
17 P-estradiol 
Oral contraceptives 
Oral contraceptives 
Sister chromatid 
exchanges, DNA 
fragmentation 
Sister chromatid 
exchange (SCE), 
micronucleus 
test (MN), and 
chromosome 
aberrations (CA), 
FISH procedure 
and in vitro anaphase 
and metaphase 
preparation 
analyses 
Comet assay 
Comet assay 
Sister chromatid 
exchanges (SCEs), 
micronucleus test 
(MN), and 
chromosome 
aberrations (CAs) 
2 Review of Literature 
as well as 
chromatid were 
observed, but 
dicentric, 
exchanges and 
rearrangements 
were not 
observed 
Hormones do 
not induce 
structural 
chromosome 
aberrations in 
lymphocytes 
and indicate that 
ethynilestradiol 
and norgestrel 
have an 
aneugenic effect 
on fibroblast 
and lymphocyte 
cultures 
Comet assay to 
assess 
genotoxicity in 
female human 
populations 
Lymphocytes 
from women at 
leuteal phase 
with high level 
of progestone 
and estradiol 
showed DNA 
damage 
Increase risk of 
chromosomal 
imbalances 
Bukvic et al.. 
(2000) 
Baj payee et 
al., (2005) 
Braz and 
Salvadori, 
(2007) 
Landi and 
Barale, (1999) 
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3, QENOTOXIC DAMAGE IN CULTURED HUMAN PERIPHERAL 
BLOOD LYMPHOCVtES OF ORAL CONTRACEPTIVE USERS 
3.1. Introduction 
Oral contraceptives are the combination of estrogen and progesterone. They 
are used to treat various hormonal disturbances, premenstrual syndrome and ovarian 
cysts (Speroff e? a/., 1999). The composition of pills varies from country to country 
due to the responsiveness variation from individual to individual or one population lo 
another (Goldzieher, 1990). Earlier reports suggest the genotoxic effects of synthetic 
progestins in cultured human peripheral blood lymphocytes (Kochhar, 1988; Shyama 
and Rahiman, 1996; Siddique and Afzal, 2005c; Siddique et al., 2006b; Joosten et al; 
2004). In these studies the genotoxic effects were observed at a very high dose and the 
reactive oxygen species was (ROS) suggested as a causative agent for the genotoxic 
damage (Siddique and Afzal, 2004b; Siddique et al., 2005a). The conversion of 
estrogen into catechol estrogens and quinines via redox reactions cause oxidative 
damage to DNA (Siddique and Afzal, 2005; Siddique et al, 2005b). There are both 
positive as well as negative reports regarding the genotoxic effects of estrogens and 
synthetic progestins (Littlefield and Mailhes, 1975; Hundal et al, 1997; Dhillon et al, 
1994). In the present study an attempt has been made to investigate the possible 
genotoxic effects among oral contraceptives (OCs) users (females) by using 
chromosomal aberrations, sister chromatid exchanges and DNA damage as a 
parameters. 
3.2. Materials and Methods 
3.2.1. Chemicals 
RPMI 1640, fetal calf serum, phytohaemagglutinin-M, antibiotic-antimycotic 
mixture (Invitrogen); 5-bromo-2-deoxyuridine, Giemsa stain (Merck, India), 
Tris.HCl, EDTA, Triton-X, Trichloro acetic acid and diphenylamine, colchicine 
(SRL, India). 
3.2.2. Human Lymphocyte Culture 
A sample of heparinized venous blood was obtained from 25 women taking an 
OCs preparation containing levonorgestrel and ethinylestradiol as a content for 12 
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months as a means of contraception following their first pregnancy. Age matched 
healthy 25 controls were evaluated along with the above subjects. A written informed 
consent was obtained from all subjects. The mean age of 25 women using OCs was 
28.5 years and of the 25 controls was 27.5 years. Individuals answered a questionnaire 
relating to lifestyle factors. The OC users were not having any other addictions such 
as smoking, alcohol drinking etc nor have any history of disease. Briefly, heparinised 
blood sample (0.5 ml), was obtained from each female and was placed in a sterile 
cultured tube containing 7 ml of RPMI 1640 medium, supplemented with fetal calf 
serum (1.0 ml), antibiotic-antimycotic mixture (l.O ml) and phyto-haemagglutinin-M 
(0.1 ml). The culture tubes were placed in the incubator at 37°C for 48 hr (Carballo et 
al, 1993). 
3.2.3. Chromosomal aberration analysis 
After 47 hr, an amount of 0.2 ml of colchicine (0.2 |ig/ml) was added to the 
culture tubes. Cells were centrifiaged at 800 g for 10 min. The supernatant was 
o 
removed and 8 ml of pre warmed (37 C) 0.075 M KCl (hypotonic solution) was 
added. Cells were re-suspended and incubated at 37 C for 15 min. The supernatant 
was removed by centrifugation at 800 g for 10 min and subsequently 5 ml of chilled 
fixative (methanol:glacial acetic acid; 3:1) was added. The fixative was removed by 
centrifiigation and the procedure was repeated twice. The cells were stained in 3% 
Giemsa solution in phosphate buffer (pH 6.8) for 15 min. About 300 metaphases were 
examined for the occurrence of different types of abnormality. Criteria to classify 
different types of aberrations were in accordance with the recommendation of 
Environment Health Criteria 48 for Environment Monitoring of Human Population 
(IPCS, 1985). 
3.2.4. Sister chromatid exchanges 
For sister chromatid exchange analysis, bromo deoxyuridine (10 |ag/ml) was 
added at the beginning of the culture and the mitotic arrest was attempted 1 hr prior to 
harvesting by adding 0.2 ml of colchicine (0.2 |ag/ml). Hypotonic treatment and 
fixation were performed as described for chromosomal aberration analysis. The sister 
chromatid average was taken from an analysis of metaphase during second cycle of 
division. A total of 25 well spread metaphases were scored for individual (Perry and 
Wolff, 1974). 
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3.2.5. Quantitative assay for DNA fragmentation 
Quantitative assay for DNA fragmentation was performed according to 
protocol of Burton (1956). After incubation of 48 hr, the cell suspension containing 1-
10x10* cells in a 1 ml volume was prepared for each donor. About, 0.8 ml of cell 
suspension was transferred to a micro centrifuge tube and 0.7 ml of ice cold lysis 
buffer (5mM Tris CI, pH 8.0/20mM EDTA/0.5% (v/v Triton X-100) was added. The 
o 
tubes were vortexed and allowed to lyse for 30 mm at 4 C. The tubes were centrifuged 
for 15 min at 15,000g (4 C) and the supernatant was transferred to a labelled conical 
glass tube. About 0.65 ml of 5% trichloroacetic acid (TCA) was added to the pellet in 
a micro centrifuge tube and 1.5 ml of 10% TCA to the sample in a labelled glass tube. 
o 
The sample was allowed to precipitate overnight at 4 C. The tubes were then 
centriftiged for 10 min at 2500 g at room temperature and the supernatant was 
removed and about 0.65 ml of 5% TCA was added to the pellet. The tubes were 
boiled for 15 min at 1OOC in a water bath. After cooling down to room temperature 
the samples was centriftiged at 2500 g for 5 min. About 0.5 ml of each supernatant 
(from both glass and micro centriftige tubes) was added to the labelled glass tube. 
About, 1 ml of diphenylamine reagent was added to each tube and was incubated for 4 
hr at 37 C (Siddique et al., 2010). Finally the absorbance were noted at 600 nm in a 
spectrophotometer and the results were expressed in percentage of DNA fragmented 
as follows: 
% Fragmented DNA = absorbance of supernatant 
absorbance of supematant+pellet 
3.2.6. Statistical analysis 
Student's t-test was used for the analysis of data obtained for chromosomal 
aberrations and sister chromatid exchanges and ^ (Chi-square) was applied for the 
analysis of DNA damage. 
3.3. Results and Discussion 
The frequency of cells with aberration in OC users was almost similar to their 
age matched controls. Gaps and breaks of chromosome as well as chromatid were 
observed, but dicentric, exchanges and rearrangements were not observed. The mean 
values obtained were not statistically significant (Table-3.1.). A significant difference 
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(p > 0.05) in the number of SCEs/cell was observed between OC users (3.9 ± 0.076) 
and their age matched control (2.62 ± 0.068) (Table-3.2.). The mean value for the 
DNA damage was (0.1172 ± 0.0020) in OC users and (0.1148 ± 0.0025) in controls. 
The values were not statistically significant (Table-3.3.). 
The results of the present study suggest that the OC users have a significantly 
higher frequencies of SCEs/cell, but the CAs and DNA damage were not significant. 
An increase in the frequencies of SCEs and CAs has been reported during pregnancy 
(Murthy and Prema, 1983; Ghosh and Ghosh, 1988). The concentration of the 
estrogens is increased during pregnancy, which may be the possible reason of an 
increase in SCEs (Sharma and Das, 1983). Earlier studies performed on the genotoxic 
potential of steroids have shown to cause chromosomal damage, induction of SCEs 
and formation of endogenous adducts (Blakey and White, 1985; Shimomura et ai, 
1992; Yager and Fifield, 1982; Joosten et al, 2004). The results of the present study 
shows that the OCs are not potent in inducing DNA damage/chromosomal 
aberrations, but are able to increase the number of SCEs/cell. The study performed by 
Biri et al, (2002) also showed the increase in SCEs/Cell in OC users. The SCEs are 
the cytological manifestation of interchanges between DNA replication products at 
apparently homologous loci. It is more sensitive indicator of genotoxic effects than 
structural aberrations (Tucker and Preston, 1996; Tucker et al., 1993). The induction 
of SCE is also correlated with the induction of cancer (Gebhart, 1981). Besides 
various reports on the genotoxicity of steroids some of the progestogens have been 
studied in short and long term toxicology studies in rodents, dogs and monkeys for 
their carcinogenic activity, no significant or unusual toxicities were reported (Jordan, 
2002). In some cases the oral contraceptives have also been suggested to be having a 
role in preventing ovarian cancer by both suppressing ovulation and altering the 
tumour promoting milieu (Siskind et al, 2000). 
The results obtained in the present study are contrary to the studies performed 
by other workers (Fridrichova, 1990; Pinto, 1986; Dhillon et al, 1994). This may be 
due to the new hormonal formulations and preparations developed in an attempt to 
reduce the adverse effects of OCs, such as the reduction in the estrogen content. 
Estrogen such as ethinylestradiol, in the liver undergoes aromatic hydroxylation and 
the product, 4-hydroxyestrone, 3, 4-dihydroxy 1,3,5 (10)-oestratien-17-one (4-OHE) 
is carcinogenic in male Syrian golden hamster kidney tumor model (Liehr et al, 1986 
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Table 3.2. Distribution of Sister ciiromatid exchanges (SCEs) among women using oral 
coniracepiives (OCs). 
1 Subjects 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Mean ± SE 
SCE 
OC users 
42 
4.1 
4.3 
3.9 
3.5 
3.6 
3.7 
3.3 
3.7 
3.8 
4.1 
4.0 
3.2 
3.2 
3.3 
4.2 
4.1 
4.3 
4.4 
4.0 
4.3 
4.2 
4.1 
3.9 
4 4 
3.91 ±0.076* 
per cell 
Control 
23 
2.5 
2.9 
2.7 
2.4 
2.3 
2.6 
3.1 
2.2 
2.3 
2.4 
2.5 
3.2 
2.9 
2.8 
27 
3.2 
2.2 
2.8 
2.7 
2.4 
2.3 
2.8 
2 I 
3.3 
2.62 ± 0.068 
'pXJ.U!) (Signiticant with respect to control). 
Table: 3.3. Estimation of DNA damage among Oral contraceptives (OCs) users and non-users. 
Subjects 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
vfesR ± SE 
OC users 
0 11 
0.12 
0.12 
0.13 
0.12 
0.10 
0.11 
0.13 
0.14 
0.12 
0.11 
0.10 
0.11 
0.12 
0.11 
0.13 
0.13 
0.12 
0.12 
0.12 
0.11 
0.12 
0.11 
0.10 
0.12 
0.!! 72 ± 0.0*^20 
Controls 
0.10 
0.11 
0.12 
0.11 
0.12 
0.13 
0.13 
0.12 
0.11 
0.09 
0.08 
0.11 
0.12 
0.11 
0.12 
0.13 
0.11 
0.12 
0.12 
0.13 
0.12 
0.11 
0.10 
0.12 
0.13 
0. II48 ± 0.00252 
p>0.05 NS (Non significant) 
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Li and Li, 1987). The genotoxic potential of steroids is determined by the metabolic 
conditions in the test system and the human body. The extrapolation from the 
experimental data to humans is not only difficult but also complex. The most of the 
studies conducted for genotoxic potential of steroids involve the concentration m 
microgram per ml range whereas the therapeutic plasma concentration ranges from 
nanogram or picogram per ml (Joosten et al, 2004). 
3.4. Conclusion 
The present study was conducted on the women taking OCs for one year and 
the increase in SCEs may be due to the variable hormonal profile among them. 
Further, the occupation and work place, polymorphic metabolizing genes and 
efficiency of DNA repair can also affects the response against OCs. 
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4.1. Introduction 
From the last few decades, world is facing the most serious problem of 
population explosion. Contraception method is used worldwide for over birth control 
or unwanted pregnancies. Many workers have suggested that the use of contraceptives 
is beneficial, but it may also have some side effects too. The researchers believe that 
the widespread use of hormonal contraceptive provides an opportunity for assessing 
the influence of estrogens and progesterone on various biochemical parameters among 
users. Synthetic progestins not only have genotoxic potential (Siddique and Afzal, 
2004a; Siddique and Afzal, 2005a; Siddique et al., 2005a,b,c; 2006a,b) but are also 
vulnerable to various types of cancer (Siddique and Afzal, 2008; Siddique and Afzal, 
2005b). It was found that the bone formation was significantly decreased in women 
taking oral contraceptive pills (Gamero et al., 1995). Some remarkable findings are 
well documented by workers which showed that oral contraceptives are involved in 
many diseases such as, myocardiac infraction, and carcinogenicity (Obisesan et al.. 
2002; Tzankova et al., 2010; Naz et al., 2012b). An increase in the risk for ischemic 
stroke in women taking oral contraceptives has been reported (Thorvaldsen et al.. 
1995; Vessey et al., 1984; WHO, 1996) and other studies showed that oral 
contraceptives also increases the risk for venous thromboembolism (Farmer and 
Lawrenson, 1998; Weiss, 1999; Westhoff, 1998; Rosing and Tans, 1999; Kemmeren 
et al., 2001). The relationship between oral contraceptive users and the risk for breast 
cancer remains controversial. Most studies suggests no overall risk or a slight 
increased risk of breast cancer in women using oral contraceptives (Anonymous 1986; 
Marchbanks et al., 2002; Brinton et al., 1998; Hankinson et al., 1997). It has been 
reported that the serum total cholesterol is significantly higher among oral 
contraceptive users as compared to non users (Nawrot et al., 2003). The mode of 
action depends upon the formulation of pills. The pills possibly inhibits ovulation by 
the formation of pituitary luteinizing hormone that renders the cervical mucus hostile 
to sperm penetration. The oral contraceptive pills (OCPs) are the combination of 
different concentrations of estrogen and progestin. In our present study the 
composition of the oral contraceptive taken by the women was: Ethinyl Estradiol 
(EE2) (0.03 mg) and Levonorgestrel (0.15 mg). In the present study an attempt has 
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been made to investigate the possible effects of oral contraceptives (OCs) among 
users on high density lipoprotein cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), total cholesterol (TC) and triglycerides (TG). 
4.2. Materials and Methods 
4.2.1. Sample Size 
The subjects for the study were married women of low income group to a total 
of 100 participants from Malkhan Singh hospital and Jawahar lal Nehru Medical 
College of Aligarh city, who were of 21 to 40 years of age, among which 55 women 
were taking combined oral contraceptives preferring after 8-10 days of withdrawl 
period and 45 non-users healthy married women who were not taking any oral 
contraceptive. A random sampling were performed and the women taking oral 
contraceptive continuous for the three months were included for the comparison to 
non-users. A written consent was obtained from the subjects for taking their blood 
samples. The detailed questionnaire includes some issues about fasting, age, health 
history, nature of menstrual cycle, bleeding, disease, etc. 
4.2.2. Blood sampling and processing 
In morning as overnight fasting of users and non-users women, about 4 ml 
blood was collected in vacutainer tube with clot activator from each women in study 
sample. The serum samples were obtained by centriftigation at 3000 rpm for 15 min 
and the sera was stored at -20°C and analyzed within three days. 
4.2.3. Blood parameters 
The analysis of lipid profile of cholesterol, triglycerides High-density 
lipoprotein (HDL-C) and Low-density lipoprotein LDL-C were carried out using a 
commercially available diagnostic test kits (Crest Biosystems kits, India). 
4.2.4. Lipid profile 
Estimation of Total serum Cholesterol (TC) 
Principle 
TC was determined by CHOD/PAP method in which cholesterol is determined 
after enzymatic hydrolysis and oxidation. Cholesterol esterase hydrolyses esterified 
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cholesterol to free cholesterol. The free cholesterol is oxidized to form hydrogen 
peroxide which further reacts with pheivol and 4-aminoantipyrine by the catalytic 
action of peroxidase to form a red coloured quinoneimine dye complex. The mtensity 
of the colour formed is directly proportional to the amount of cholesterol present in 
the sample. 
^1 , , , TT ^ Cholesterolestrase ^, , , , ^ 
Cholesterol esters + H2O ->-Cholesterol+ Fatty acid 
Cholesterol+ O2 ^ Cholestenone + H2O2 
H2O2+4 Aminoantipyrine+Phenol >- Red Quinoneimine dye + H2O 
Estimation of Triglycerides (TG) 
Principle 
TG was determined by GPO/PAP method. In this method, lipoprotein lipase 
hydrolyses triglycerides to glycerol and free fatty acids. The glycerol formed with 
ATP in the presence of glycerol kinase forms glycerol- 3- phosphate which is 
oxidized by the enzyme glycerol phosphate oxidase to form hydrogen peroxide. The 
hydrogen peroxide further reacts with phenolic compovmd and 4-aminoantipyrine by 
catalytic action of peroxidase to form a red coloured quinoneimine dye complex. 
Intensity of the colour formed is directly proportional to the amount of triglycerides 
present in the sample. 
^ . , ., Lipoprotein lipase 
Triglycerides ». Glycerol Free fatty acids 
„, , , Glycerol kinase 
(jlycerol-r ATP *- QlyceroBphosphate + ADP 
GlyceroBphosphate +O2 G'ycero'3PQ» Dihydroxyacetone+H2O2 
H2O2+ 4 aminoantipyrine Peroxidase^ ^^^ Quinoneimine+H2O2 
Estimation of Heavy Density Lipoproteins-Cholesterol (HDL- C) 
Principle 
(HDL-C) determined by PEG precipitation method. The estimation of HDL-C 
involved precipitation of LDL and VLDL from serum by polyethylene glycol. 
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Polyethylene glycol 
Serum — ~—*- HDL+ LDL+VLDL 
When serum is reacted with PEG contained in the precipitating reagent all VLDL and 
LDH were precipitated. The HDL remained in the supernatant and can be assayed as a 
sample for cholesterol using Cholesterol (CHOD/PAP) reagent. 
Estimation of Low-density lipoprotein LDL-C 
Estimation of Low Density Lipoproteins-Cholesterol (LDL-C) was estimated 
by Freidewald's Formula as follows: 
LDL Cholestrol (mg/dl) = Total Cholesterol- [Triglycerides] - (HDL Cholesterol) 
5 
4.2.5. Statistical analysis 
The obtained data was analyzed by using a software statistical package SPSS 
version 16.0. Students t-test was also used to differentiate between two numerical 
data. 
4.3. Results and Discussion 
The results of the present study suggest that the oral contraceptive users have 
higher level of total Cholesterol, HDL-C, LDL-C and triglycerides as compared to 
non-users. As shown in the Table-4,1., the mean values of Cholesterol 
(242.92±2.842), HDL-C (58.65± 1.098), LDL-C (I15.84±1.266) and triglycerides 
(105.56±2.341mg/dL) were significantly higher among users as compared to the non-
users (total Cholesterol 218.49±1.762, HDL-C 48.17±0.543, LDL-C 100.32±0.951 
and triglycerides 83.77±2.299mg/dL) (Fig.4.1.). 
It has been observed that the LDL-C and HDL-C increase is prone to have 
stroke and myocardial infarction in women taking oral contraceptives (Wynn and 
Doar, 1966). The present study supports the earlier studies carried out on lipid profiles 
of women using OCs (Emokpae et al., 2010; Abdel-Barry et al., 2011). Elevated 
serum levels of lipids are probably the most important biochemical risk factors for 
atherosclerosis. In the liver triglyceride synthesis is enhanced by estrogen and 
inhibited by androgen and these triglycerides are partly brought into the circulation as 
low-density lipoproteins. When a contraceptive pill containing an estrogen and a pro-
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labie- 4.1. Lipid profile of oral contraceptive (OC) users and non-users women. 
Lipid Profile mg/dl -J OC users (n = 55) Non-users (a=4S) 
t^noiesieroi 
HDL-C 
LDL-C 
Trielvcerides 
242.92 ± 2.842'" 
58.65 ±1.098" 
115.84 ±1.266' 
105.56 ±2.341^ 
48.17 ±0.543 
100.32 ±0.951 
83.77 ± 2.299 
Values arc as McaniSE, ''p<0.05 (significant Vvith respect to non-users) 
300 
250 -
200 
150 
100 
50 -
^ Users 
Non Users 
% 
mm 
cholesterol HDL- C LDL-C Triglycerides 
Figure. 4.1. Lipid profile of oral contraceptive users and non-users. 
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-gestogen is introduced, the resultant effect is not predictable. The clinical 
significance of this observation is supported by the fact that atherosclerosis begins 
early in life and is accelerated in the presence of high cholesterol and serum 
triglycerides (Newman et ai, 1991). Contraceptive steroids having a combination of 
an estrogen and progestin or only progestin are effective and reversibly regulate 
fertility. Combined oral contraceptives affects a variety of metabolic factors including 
hemostatic variables and estrogen-sensitive liver proteins and these effects can be 
modulated by the type of estrogen and progestin in a given combination (Sitruk-Ware 
and Nath, 201 J). The estrogen component of OCs has been reported to increase the 
production of very low density lipoprotein (VLDL) and high density lipoprotein 
(HDL) but reduce the level of low density lipoprotein (Sitruk-Ware, 2006). The 
reduction in the doses of levonorgestrel/ethinyl estradiol containing contraceptives 
from 30-20 ^g (EE) and that of 150-100 ^g (levonorgestrel) resulted in the less 
adverse effect on the lipid profile and have been suggested to lower the incidence of 
thrombosis as compared to other EE based contraceptives (Skouby et al., 2005). OCs 
containing levonorgestrel was associated with an almost four times higher risk of 
venous thrombosis as compared to non-users (Van Hylckama Vlieg et al., 2009). The 
intake of 100 \ig levonorgestrel with 20 |ig ethinyl estradiol to 28 women whom were 
at the risk of pregnancy shows a little change in lipid profile as compared to higher 
dose oral contraceptive preparation (Young and DelConte, 1999). Despite the 
changes in lipid profile among users of higher dose oral contraceptive agents, there is 
little and no effect on the long term risk artherogenic cardiovascular disease (Stampfer 
et al., 1990). The status of elevated serum triglyceride level may be an independent 
predictor of coronary heart disease as ethinyl estradiol increases hepatic secretion of 
triglyceride rich lipoprotein (Avins et al., 1989; Schaefer et al., 1983). The progestin 
component of the OC may oppose this increase. The injectable oral contraceptives 
have also been reported to increase the levels of triglycerides, total cholesterol, high 
density lipoprotein (HDL) cholesterol in the serum (Godsland et al., 1990). 
4.4. Conclusion 
The lipid profile depends on the brand of OCs or duration of their use. The 
users in our present study were taking OCs of ethinyl estradiol (0.03 ^g), 
levonorgestrel (0.5 |ig). The increase in the lipid profile may be attributed to their 
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responsiveness towards the drug. However the long term effects were not taken into 
account in the present study, but still there is a need of a detailed study taking the 
various life style factors into the consideration. 
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5. EFFECT OF ORAL CONTRACEPTIVE PILLS ON THE BLOOD 
SERUM ENZYMES AND ONA DAMA6E IN LYMPHOCYTES AMONa 
USERS 
5.1. Introduction 
Women use exogenous female hormones as oral contraceptives (DCs). Over 
several decades the side effects of OCs are of major public health interest. Their 
association with ovarian cancer in particular has occupied an attention of man> 
epidemiologists (Siskind et al., 2000). Soon after the introduction of OCs pills 
numerous side effects among users were reported (Weiderpass et al., 1999). The 
contraceptive containing either a combination of an estrogen and progesterone or 
progesterone only is being used by millions of women (Palan et al., 2010). The most 
effective contraceptive works by suppressing the levels of follicle-stimulating 
hormone and luteinizing hormone i.e. by reducing metabolic activity of ovary, 
including the suppression of ovulation (Petitti, 2003). Currently there are several 
hormonal methods available other than oral pills such as transdermal patches, vaginal 
rings and intrauterine systems (Palan et ah, 2010). Few research evidences suggest 
that oral contraceptive pills might have negative effects on health of the women rather 
than the prevention of pregnancies, such as such as coronary atherosclerosis and 
myocardial infarction (Engel et at., 1983; Jick et al., 1996; Lewis et al, 1997; Dunn 
et al, 1999; Tanis et al, 2001; Sidney et al, 1998), risk of breast cancer (Grabrick et 
al, 2000; Rosenberg et al, 2009; Stanford et al, 1989) and hepatocellular carcinoma 
(Neuberger et al, 1986). In the present study blood serum enzymes such as alkaline 
phosphatase (ALP), gamma-glutamyltranseferase (GOT), lactate dehydrogenase 
(LDH), amino transeferases (SGOT and SGPT), serum proteins (albumin and 
globulin) and DNA damage in the peripheral blood lymphocytes were studied among 
women of different age groups using OCs for various durations. 
5.2. Material and Methods 
5.2.1. Sample size 
About 600 subjects were included in the study from Jawahar Lai Nehru 
Medical College of Aligarh Muslim University, Aligarh, who were 16 to above 40 
years of age. Among them 300 women were taking oral contraceptives preferring 
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continuous months and 300 were non-users healthy women with regular menstrual 
cycle who were not taking oral contraceptives. The detailed questiormaire includes 
some issues such as age, health history, type of pill, nature of menstrual cycle, any 
other disease, smoking habit, alcoholism, bleeding etc. About 64% of women were 
taking OCs as birth control, 15% for irregular bleeding, 11% for dysmenorrhea/pelvic 
pain, 6% for premenstrual syndrome and 4% for menorrhagia. A written consent was 
taken from each subject taking participation in the study. 
5.2.2. Blood sampling and processing 
After overnight fasting, about 2 ml of blood was collected in a vacutainer tube 
with a clot activator from women in the study sample. The serum was obtained by 
centrifugation at 3000 rpm for 15 min and analyzed for various enzyme activities. 
5.2.3. Blood Serum analysis 
The blood serum was analyzed for enzymes: ALP, GGT, LDH, 
aminotransferases (SGPT and SOOT) and serum proteins (albumin and globulin) 
among users and non-users by using commercially available diagnostic test kits (Crest 
Biosystems kits, India). 
5.2.4. Enzyme profile 
Alkaline phosphatase (ALP) 
Principle 
ALP was determined by (Modified Kind & King's Method) in which an 
alkaline pH hydrolyses di sodium phenylphosphate to form phenol. Further phenol 
reacts with 4-aminoantipyrine in the presence of potassium ferricyanide, as an 
oxidising agent, to form a red coloured complex. The intensity of the colour formed 
is directly proportional to the activity of ALP present in the sample. 
ALP di Na Phenylphosphate + H2O >- Phenol + di Na Hydrogen phosphate 
. , ^ A • .• • Alkaline Medium „ , , , , 
Phenol+4-Ammoantipyrme *- Red coloured complex 
K3Fe(CN)6 
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y-Glutamyl transferases (GGT) 
Principle 
GGT was determined by (Carboxy substrate Method) in wliidJIl tl' UUlalyzes 
the transfer of amino group between L- y- Glutamyl-3-carboxy-4nitroaniiide and 
Glycylglycine to form L- y- Glutamylglycylglycine and 5-amino-2-nitrobenzoate. The 
rate of formation of 5-amino-2-nitrobenzoate was measured as an increase in 
absorbance which is proportional to the GGT activity in the sample. 
L-Gamma-Glutamyl-3-Carboxy-4-Nitroanilide ^^ • L-GammaGlutamyigiycylglycine 
5-amino-2-nitrobenzoate 
Glycylglycine 
Lactate dehydrogenase (LD) 
Principle 
Lactate dehydrogenase (LD) was determined by [lactate dehydrogenase (P-
L) modified IFCC method]. Lactate dehydrogenase catalyzes the reduction of 
pyruvate with NADH to NAD. The rate of oxidation of NADH to NAD was measured 
as a decrease in absorbance which is proportional to the LDH activity in the sample. 
LDH 
Pyruvate + NADH + H^ *- Lactate + NAD 
Aminotransferases (SGOT and SGPT) 
Principle of SGOT (ASAT) 
SGOT (ASAT) was determined by (Reitman & Frankel's method). SGOT 
converts L-aspartate and a-ketoglutarate to oxaloacetate and glutamate. The 
oxaloacetate formed reacts with 2,4 Dinitrophenyl hydrazine to produce a hydrazone 
derivative, which is in alkaline medium produces a brown coloured complex. The 
calibration curve was plotted using a pyruvate standard. 
L-Aspartate + Ketoglutarate ^ ^ ^ ^ *- Oxaloacetate + L-Glutamate 
pH7.4 
a 
Oxaloacetate + 2,4, DNPH - ^ ^ 2, 4, Dinitrophenyl Hydrazone 
(Brown colour complex) 
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Principle of SGPT (ALAT) 
SGPT (ALAT) was determined by (Reitman & Frankel's method). SGPT 
converts L-alanine and a ketoglutarate to pyruvate and glutamate. The pyruvate 
formed reacts with 2,4 dinitrophenyl hydrazine to produce a hydrazone derivative, 
which in alkahne medium produces a brown coloured complex whose intensity was 
measured. 
L-Alanine +a Ketoglutarate » Pyruvate + L-Glutamate 
pH 7.4 •' 
AI K 3 i m p 
Pyruvate + 2,4, DNPH ^ .. >- 2, 4, Dinitrophenyl Hydrazon 
(Brown colour complex) 
Serum proteins (albumin and globulin) 
Principle 
Albumin and Globulin were determined by BCG method. Albumin binds with 
the dye Bromocresol Green in a buffered medium to form a green coloured complex. 
The intensity of the colour formed is directly proportional to the amovmt of albumin 
present in the sample. 
Albumin + Bromocresol Green >-Green Albumin BCG Complex 
5.2.5. Single cell gel electrophoresis (SCGE) 
5.2.5.1. Blood sampling for Comet assay 
After overnight fasting, about 2 ml of blood was collected in a heparinised 
vacutainer tube from each woman (user and non-user). The blood lymphocytes were 
isolated by Ficoll-Histopaque density gradient centrifiigation and washed in PBS. 
5.2.5.2. Slide preparation and Electrophoresis 
The alkaline SCGE technique of Singh et al. (1988) was followed. The half 
frosted slides were covered with 1% normal melting agarose (NMA) at about 45°C in 
PBS. The slides were immediately covered with a coverslip and kept at room 
temperature for about 5 min to allow the agarose to solidify. This layer was followed 
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by the second layer of 0.5% LMA. Five to 10 ^1 of cell suspension was mixed with 75 
|j,l of 0.5% LMA for embedding on slides. After gently removing the coverslip the 
cell suspension was laid onto the first agarose layer, spread out with a coverslip, and 
maintained on an ice-cold flat tray for 5 min to solidify. After removal of the 
coverslip the slides were immersed in cold lysing solution (2.5 M NaCl,100 mM 
EDTA,10 mM Trizma base, 0.2 mM NaOH, pH 10), 1% Triton X-100 and 10% 
DMSO for overnight at 4°C. The slides were then removed from the lysing solution, 
drained and placed in a horizontal gel electrophoresis tank near the anode. The tank 
was filled with fresh electrophoresis buffer (ImM Na2EDTA and 300mM NaOH. pH 
13) to a level approximately 0.25 cm above the slides. Before electrophoresis, the 
slides were left in the buffer for 20 min to allow the unwinding of the DNA. 
Electrophoresis was conducted at 1.6 V/cm for 20 min (300 mA) at room temperature. 
All steps were conducted under dimmed light (tank was covered with a black cloth) to 
prevent the occurrence of additional DNA damage. After electrophoresis, the slides 
were taken out of the tank. Tris buffer (0.4M Tris, pH 7.5) was gently added drop 
wise to neutralise the excess alkali. The neutralising procedure was repeated three 
times. 
5.2.5.3. Staining 
To each slide, 65^1 ethidium bromide (EtBr-20^g/ml) was added. The slides 
were covered with a cover-slip, placed in a humidified air-tight container to prevent 
drying of the gel and analysed within 3-4 hr. 
5.2.5.4. Slide scoring 
About 50 cells were scored per slide (3 slides/subjects) were scored randomly 
and analyzed with Cometscore^'^ software (version 1.5, TriTek Corporation, 
Sumerduck). DNA tail length was measured and expressed as arbitrary unit. 
5.2.6. Statistical analysis 
The obtained data was analyzed by using a software statistical package SPSS 
version 16.0. Students t- test was applied for the significant difference among users 
and non users. One-way analysis of variance (ANOVA) using post hoc tukey test was 
applied to compare the differences amongst the users of different age groups. 
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5.3. Results and Discussion 
Table- 5.1. shows the age distribution of OCs users and non-users. Table-5.2. 
shows the distribution of users according to the duration of using OCs. The more 
number of users were of 26-30 years of age group. Table-5.3. describes the 
composition of OCs used by the women. The highest concentration of estrogens in the 
combined oral contraceptives was BO i^g. Table 5.4. shows the distribution of various 
blood serum enzymes in women of different age groups. As is evident from the Table-
5.4., a significant decrease in the ALP (U/L) was observed among the users of all age 
groups as compared to their respective age group non-users (p<0.05). Concerning the 
other enzymes such as LDH (U/L), SCOT (U/L), SGPT (U/L), and GOT (U/L), a 
significant increase in their levels were found among users of all age groups as 
compared to non-users to their respective age groups (p<0.05). The level of serum 
albumin was also found to be decreased significantly among users of all age groups 
compared to non users of their respective age group (p<0.05) (Table-5.4.). The level 
of serum globulin was found to be significantly higher among users of all age group 
compared to non users of their respective age group (p<0.05) (Table 5.4.). Table-5.5. 
shows the enzyme profile according to the duration of using the OCs. A duration 
dependent significant decrease (r= -0.99) in serum ALP was found as compared to the 
non users (p<0.05) (Table-5.5.). In other serum enzymes LDH (r= 0.97), SCOT 
(r=0.98) and SGPT (r=0.99) and GGT (r=0.99) a duration dependent significant 
increase was found as compared to the non-users (p<0.05) (Table-5.5.). The serum 
albumin level (r=0.99) was also found to be decrease among users in accordance with 
increase in the durafion of use of OCs (p<0.05) (Table-5.5.). The serum globulin level 
was found to be increase among users (r=0.98) with increase in duration of the use of 
OCs. The results obtained for comet assay performed on the human peripheral blood 
lymphocytes of users and non-users is shovm in Figure 5.1. (a &b). Among women 
using OCs for 1-6 months showed 1.73 fold (p<0.05), increase in the mean tail length 
as compared to control (Fig. 5.2.). The women using OCs for more than six, thirteen 
and nineteen months showed 2.20. 2.40 & 2.74 folds significant increase respectively, 
in the mean tail length as compared to non users (p<0.05). 
Hormonal contraceptives are in clinical practice for more than 70 years for the 
prevention of ovulation, implantation and sperm penetration into ovum. Estrogen or 
progesterone or both are also used in hormonal replacement therapy and are given to 
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Table-5.1. Age distribution of oral contraceptives non-users and users. 
Age Groups 
(Years) 
16-20 
21-25 
26-30 
31-35 
36-40 
>41 
MeaniSD 
Non- users (N=300) 
30 
55 
89 
34 
48 
44 
30.61±8.20 
Users (N=300) 
31 
60 
95 
42 
30 
42 
30.42±8.4i 
1 
Tab!e-5.2. Distribution of users on the basis of using oral contraceptives. 
Duration of contraceptive 
use (months) 
1-6 
7-12 
13-18 
19-24 
MeaniSD 
OC users 
62 
79 
65 
94 
13.44±6.96 
k Combined oral contraceptives 
Desogestrel 
Levonorgestrol 
Medroxyprogesterone 
Drospirenone 
Gestodene 
Norgestimate 
Norethindrone acetate 
Desogene 
Norgestrel 
Progestin only 
Ethynodiol diacetate 
Desogestrel plus 
Levonorgestrel 
f. ^^^.^^ . . 
Progestin 
(mg) 
0.5 
0.10 
0.15 
0.10 
0.15 
0.75 
0.5 
0.10 
0.15 
0.5 
0.35 
0.3 
• ^ 
Estrogens (Ethinyl Estradiol) 
(HR) 
10 
30 
20 
10 
30 
10 
10 
30 
10 
20 
-
. 
-
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Figure 5.1. Comet assay performed in human peripheral blood lymphocytes (a) non users, 
and (b) users. 
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Figure 5.2. Histogram of the total comet tail length in control and in women taking oral 
contraceptives. [*Significant difference between oral contraceptive users and non-users 
(p<0.05)]. 
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women after menopause (Moore et al, 1999). However the hormonal replacement 
therapy has been reported to be associated with increased risk of cancer (Speroff et 
al, 1999; Pike and Ross, 2000). There are several reports on the genotoxic potential 
of estrogens and synthetic progestins in vivo and in vitro (Siddique and Afzal. 2004a; 
Siddique and Afzal, 2004b; Dom et al, 2007; Dom et al, 2008; Seraj et a/., 1996; 
Siddique et al, 2006; Siddique and Afzal, 2008; Yan et al, 2013). Most of the oral 
formulations have a definite proportion of estrogen and synthetic progesterone 
(Jordan, 2002). However the composition and salts of the OCs can vary from country 
to country so as the response toward the drugs that forms the basis of 
pharmacogenomics (Franconi and Campesi, 2014). The reports on the genotoxic 
potential in women's using steroid hormones as an oral contraceptives or HRT are 
little (Ozcagli et al, 2005; Kayikcioglu et al, 2000). 
In early 80s it was well documented that the use of oral contraceptives was 
associated with the benign hepatic adenoma. The association was fiirther confirmed 
by Palmer et al (1989). The use of OCs have been reported to be associated with the 
higher plasma retinol, 25-hydroxy vitamin D, total iron binding capacity, total 
chlolesterol, LDL-cholesterol and triacyglycerol (Thane and Bates, 2002; Naz et al, 
2012). Concerning the serum enzymes levels in our present study an increase in LDH, 
SGPT, SGOT and GOT was found among users. This increase was found to be in 
correlation with the duration of using OCs. The use of OCs has been reported to alter 
lipids and enzymes profile among OCs users (Naz et al, 2012a; Machado et al, 
2010). As most of the drugs are metabolized by liver hence it is becomes difficult to 
correlate whether larger doses of drugs can cause adaptative changes in the form of 
increasing the detoxifying enzymes, or increase in the metabolic functions of liver. 
DNA damage and increase in the frequency of sister chromatid exchanges in 
peripheral blood lymphocytes have been reported in OCs users (Naz et al, 2012b). 
The extent of DNA damage and SCEs frequency were due to the altered hormonal 
profile of the users as the damage was reported to be non significant compared to 
pregnant women (Biri et al, 2002). The increase in the mean tail length in our study 
may also be correlated to the altered hormonal profile. The increased in the DNA 
damage has been correlated with the induction of various cancers. There are reports 
on the increase in lipid profile among OCs users and increased risk of atherogenesis 
and coronary arterial disease (Santos et al, 2008). The mechanism by which 
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progestins induce tumour development is not very clear. It has been suggested that 
induction of homo oxygenases leads to the conversion of procarcinogenes to 
carcinogens (Schulte-Hermann et al, 1983), or by stimulation of the genetically 
altered pre-neoplastic cells (Ochs et al, 1986). The relationship between the 
carcinogens and sex hormones is not very clear, however a series of or combination of 
genotoxic and epigenetic changes have been reported to be associated with OC users 
(Braz and Salvadori, 2007). In our earlier in vitro studies synthetic progestins have 
been reported to generate reactive oxygen species (ROS) (Jordan et al, 2002). 
Estrogens have been reported to generation free radicals by metabolic redox cycling 
between quinone and hydroquinone forms of estrogens (Roy and Liehr, 1999), 17 P-
estradiol was repored to be mutagenic and genotoxic effects on the blood cells of 
Oreochromis niloticus (Sponchiado et al, 2011). In cultured cells northindrone has 
been reported to induce double stranded breaks (DSBs) (Gallmeier et al., 2005). In 
our present study the DNA damage was found to correlated with the duration of using 
the OCs (Y=6.6100+0.24433X; r=0.987; p<0.0047). There were no difference in the 
level of globulin in both users and non-users. Steroid hormones have been reported to 
increase aminotransferases among OC users (Siest et al., 1998; Schiele et al., 1998). 
In our earlier study with triglycerides, HDL and LDL, the level of serum markers was 
found to be high among users (Naz et al, 2012c). Thus it is concluded that the intake 
of OC effects the level of various blood serum enzymes and it may depends on the 
estrogens and progestin dosage or the androgenic activity of the progestin (Schulte-
Hermann et al, 1983). Concerning the DNA damage in blood lymphocytes, the 
damage was found to increase with increase in the duration of using OCs. Comet 
assay is a very sensitive method to estimate DNA damage at single cell level and the 
sensitivity of this test is higher than that of any other DNA damage detection method 
(SCE, MN or chromosomal aberration) (Ozcagli et al, 2005). Earlier studies have 
revealed association between DNA damage and malignancies (Smith et al, 2003; 
Colleu-Durel et al, 2001). Nearly all oral contraceptives have some amount of 
estrogens which is converted in to catecholestrogenes and result in the production of 
oxygen radicals that may cause DNA damage (Bolton, 2002). 
5.4. Conclusion 
Although estrogen are present normally in women, but the presence of it in the 
form of OCs may lead to high concentration in human body. Hence, it is suggested 
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that while prescribing OCs to the women various life style factors (cigarette 
smoking, alcohol consumption etc) that may possibly enhance DNA damage should 
be taken in consideration. The biochemical parameters (enzymatic profile of various 
blood serum enzymes) should continuously be monitored as estrogens may also act as 
tumour promoting agent due to'^ heir estrogens-receptor mediated mitogenic activity. 
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Abstract: Oral contraceptives (OC) are widely used to prevent ovulation, implantation and therefore pregnancy 
The widespread use of the oral contraceptive pills provides an opporturuty for assessing their influenL-e <.JII 
vanous biochemical parameters i e , enzymatic, serum hpid and proteins among users Recent studies have 
shown its impLcation m mar^ diseases such as thromboembolic disease, myocaididl infaictioii, ciit-ulatou 
disorders and carcinogemcity The negative effects on the hver and heart have also been reported due to h ^ h 
serum cholesterol levels among OC for their possible biochemical effects 
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INTRODUCTION 
By the early twentieth century, scientists were eager 
to isolate and wanted to determine the formulation and 
structural properties of synthetic hormones and they 
found that the high doses of these synthetic hormones 
inhibited ovulation The synthetic progesterone 
compounds that are used as an oral cc«traceptives are 
Norethisterone and Norethynodrel These compouiKls 
were first tested m woman m 1956 m the Umted States, 
Puerto Rico and Haiti The first pill that was launched as 
an oral contraceptive ioc use contdins the combination 
of nor-19 progestin with a small amount of synthetic 
estrcgen as a trade name Enovoid (Junod and Marks, 
2002) Now-a-days mdhon of women of reproductive 
age around the world use oral contraceptives 
(Burkman, 2001) Over the decades, the use of oral 
contraceptive pdls is mcreasing m India (^Sharma et al, 
2001) In recent years, it is reported that the use of oral 
contraceptive pills by women is increasing as the 
government and vanous orgaiuzations are campaigning 
for its use m order to avoid pregnancies especially m 
developing countries like Nigeria (Emckpae et al, 2010) 
Accorduig to Bukvic et al (2000) oral contraceptives piUs 
that are synthesized chemically can be carcinogenic For 
avoiding unwanted pregnancy the combmed oral 
contraceptives should be taken by users that consist of 
the steroid hormone estrogens m combinaUon with a 
progestogen (lARC, 1979, lARC, WGECRH and 
WHO, 1987) They are currently avadable m monophasic, 
biphasic and triphasic preparations, depending on the 
numbei of different doses of piogestogen Monopiiasic 
pills mamtam a constant dose of estrogens and 
progestogen, while multiphasic piUs allow a lower total 
dose ot progestogen to be given by reducing the amount 
of progestogen early m the 20-22 day penod of exposure 
Prc^estin-only ccmtraception is an option fcx women that 
contam only progestm The most common side-effects of 
progestm only c«itracep>tion is complicaUoii in 
pregnancy or eccysis and irregulanty m menstrual cycle 
(.Kauratz, 1997j Oral contracepliveb have been stiowTi 
abrupt increase m the nsk of ncn-fetal myocardial 
infarcUon (,Ory, 1977, Mann ei al, 1975j Both single 
progestins and combmed oral contraceptive shows the 
genotoxic damage and risk of Cdiicers Study slated tiidl 
steroids shows genotoxic damage at higher doses 
(Siddique et al, 2006,2005, Siddique and Afzal, 2001, The 
therapeutic doses are safe, but care should be taken with 
regard to tlieir concentiatioii as Oiey may be geiioto\ic m 
the long term use m humans (Siddique and Afzal, 2008 
Siddique et al, 2007, Siddique and Afzal, 2<iU5) The 
International Agency fca- Research on Cancer (lARC) 
concluded that progestins (progestogens) are very much 
prone to carcmcgemc to humans This nsk is probably 
due to hormonal steroids, since these steroids are very 
much carcinogemc to humans (Brambilla and Martelli 
2002) The pa'esent review gives a banei account ol the 
studies earned out on the biochemical effects of oral 
contraceptives amoi^ users 
Biochemical effects: Estrogen mcreases the serum riigti 
Density Lipoprotem Cholesterol (HDLC) levels and 
decrease the levels of Low-density Lipoprotein 
Cholesterol (LDLC), where as progestogens have a 
reverse effect i e , tliey leduce Higli-deiisity Lipopioftui 
Cholesterol (HDLC) and raise Low-density Lipoprotein 
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Cholesterol (LDLC) levels The lipoprotein profile, 
resultu^ from the use ot cral cxjntracepbve is therefore, 
dependent on the balance between the potencies of the 
ebtrogen and progestogen components Although, the 
high-dose progestogens contained in the older oral 
contraceptives did raise Low-density Lipcyrotem 
CholestCTol (LDLC) and reduce High Density Lipoprotein 
Cholesftetol level (HDLQ, modem low-dose progestogens 
do not appear to affect the lipid profile in users The 
increased risk of cardiovascular disease in oral 
contracef)tive users is due to venous or artenal 
tlnombosis (Speroff and Darney, 1996, Brennan <?/a/, 
1997) 
Several studies have been performed on the 
biochemical effect among oral contraceptives users 
Several authors have observed that the use of oral 
contraceptive pills (OCPs) may increase the risk of 
cardiovascular disease by UKreasing the levels of 
friglycendes (WHO, 1995), but the position over the 
cholesterol is not clear Wynn et al (1966) have reported 
a sigruficant difference in cholesterol levels m young 
women usu^ OCP Other authors observed a significant 
increase m all hpid fractions in women usu^ OCPs 
(Donde and Virkar, 1975; Another study showed that 
serum total cholesterol levels were higher among oral 
contraceptive users There was an increase m total 
cholesterol due to the increased in P-hpoprotein 
cholesterol A decrease m u-hpoprotem cholesterol and 
an increase m tnglycendes was also observed 
(Webber etal,\ 982) Ov er the 3 yeare of study duration, 
OC users expeneiKed an increase m the levels of 
tiiglycendes, total cholesteiol, VLDL and HDL diat were 
greater than those expenerKed by non-hcnnonal 
contraceptive users (.Berenson et al, 2009; One of the 
long-range potential ccmcems with the use of Oral 
Contraceptive Agents (OCA; is the increase in serum 
lipds Women in the OCA groqa have significantly higher 
tnglycende levels than women m the non OCAs group 
(Smith ef a/ , 1975) 
hi a stucfy on Nigenan oral contraceptive users the 
level of serum cholesterol was significantly higher as 
compared to controls 1 he elevation of serum cholesterol 
level may be due to the estrogen content m oral 
contraceptives hi conclusion, this study has 
demonstrated the need to penodically reassess the 
biochemical parameters of oral contracejAive users, 
especially those who have been on the steroids for a long 
time This is necessary in view of the subtle but 
significant biochemical changes as regards increases of 
total protein, albumin and cholesterol levels 
(Obisesan et al, 2002) Another study on biochemical 
changes on oral contiaceptive have shown the higher 
levels of tnglycendes, total cholesterol, LDL-cholesterol 
and VLDL-diolesterol m UCs users wonen The increase 
in OCP tnglycendes is due to the increase in the 
synthesis OCP intake produce changes m lipid 
metabolism m women, but such changes may not 
necessarily lead to pathogeruc concentration resulting m 
a cardiovascular disease with the prolor^ed use of not 
more tlian 4 yeais (Einokpae et al, 2010) Smce, tlie effe&tb 
caused by OCP intake are shcrt hved, it could be said that 
the effects of these hormonal prep)aratic8Ts may be 
physiologic rather than pathogenic (Karam, 2001) 
Jvlany studieb liave analyzed tlie i elation between 
cardiovascular nsk factors and oral contraceptive use m 
adult women Elevated blood levels of hpids are probably 
the most important biochemical nsk factor for 
atherosclerosis In the hver tnglycendes synthesis is 
enhanced by estrc^en and inhibited by androgen and 
these tnglycendes are partly brought into the circulation 
as low-density hpofroteins In another study it was 
observed that in adolescent girls serum total cholesterol 
was significantly higher among oral contraceptive users 
compared to non-users (Nawrot et al, 2U03) 
The effects of Oral Contraceptive Agents (OCAs) on 
lipid metabohsm were reviewed recently by Beck {] 913) 
who points out that the estrc^en-mduced nse m serum 
tnglycende levels is dose regulated and is similar to the 
general mcrease m serum tnglycendes found in 
postmenopausal women. Oral contraceptives have been 
reported to affect all serum hpids, but their effect on the 
tnglycendes and M^DL is most consistent and striking 
(Gershberg etal,\968, Molitch etal,\91 A) Some data 
also showed a small, non significant inverse lelatioiibliip 
between OC users and HDL cholesterol A recent report 
showed that different OC preparations had varying effects 
on HDL cholesterol HDL cholesterol levels appeared to 
be directly related to estrogen dose and mversely related 
to progestin dose (Bradley etal, 1978) 
Mechanism of action of oral contraceptives 
Combination oral contraceptives: Ccxnbination oral 
contraceptives are the most widely used oral 
contraceptives, that prevents pregnancy mainly by 
suppressing ovulation Both pjrogestogen and estrogen 
compKjnents sijppiress lutemizing hormone secretion, 
which prevents ovulation In addition, progestogen 
thickens cervical mucus so that sperm cannot penetrate 
the uterus and produces an endometnum that is 
unreceptive to ovum miplantation. It may also contiibute 
to contraception by interfenr^ with secretory and 
peristaltic functicxis inside the fallcpian tube 
(Hatcher et al, 1994) Estrogens and progestogens 
suppress tlie secretion of follicle-stunulating honnone. 
Int. J. Pharmacol, 2012 
which prevents the selection and emergence of a 
dominant folhcle They also minimize hreakthrough 
bleedii^ by stabihzing the endometnum so that irregular 
shedding is prevented Because the estrogen comp«ient 
potentiates the contraceptive action of the progestogen 
component (probably by mcreasing the level of 
mtiacellular progestogen receptors), only a mmimal dose 
of estrogen is needed to mauitaui the efficacy of the 
combination oral contraceptive (Speroff and 
Damey, 1996) 
Progestin-only oral contraceptives. As tlie progestogens 
themselves do not always suppress gonadotropins, 
women who take pwogestm-only oral contraceptives do 
not always ovulate The contraceptive efficacy of the 
prc^estin-only oral ccxitraceplive is therefore dependent 
mostly on its effects on cervical mucus, on the 
endometnum and possibly also on the fallopian tube 
(Speroff and Damey, 1996) The progestin-only mimpill 
must be taken every day at the same time because its 
circulatir^ progestogen level is about 75% lower than the 
level resulting trom a ccxnbination oral contraceptiv e L se 
of the mmipill may result in irregular menstrual bleedmg 
andtlK develofjment of funcUonal ovarian follicular cysts 
MmipiUs containing levoncsgestrel have been associated 
with acne The acne is caused b> the androgenic acu\ lu 
of the unopposed prc^estogen, despite its very low dose, 
which (fecreaseb tlie level of ciioulatuig sex hoiuiune 
binding globulin. As a result, biologically available levels 
of lev onoigestrel and testcsterone are increased 
Low-dose ccMnbmation oral contracepjtives do not 
produce acne because esliugen, wliich iiit-ieas>es ^cx 
hormone bmdmg globulin, counteracts the effect of 
progestogen i^ Spieroff and Damey, 1996) The mimpili Joes 
not significantly affect hpid levels, carbohydrate 
metabolism, or blood coagulauon When ii ib 
discontinued, fertility returns promptly (Hatclwr et al 
1994) 
Studies earned out on the biochemical effects on oral 
contraceptives are as given in Table 1 
Tihle 1 SludCT oo hodwrntil effecte of oat coctnctohvcs 
Oral coBteicctitivc Pinmtter itndtd Cooduaon Autbor 
E<ro«eo coattmniR oral cuiMnuUive 
Oni pU (Dipinflc OC), Viguul nng 
(Nii»«Kiii«). lymwlcnnil pifafa (Ortho Evra) 
Blood preMureMdwniinlipidt 
Upid idhiit Anticgadnt and 
S«nm lends of tnzvme 
ffilJMTlevelofsenimh|idindlowcrblcodia»ssure Webbo-tfai (1982) 
Low hpid senim level, decreise coenzyme 8„ and 
toUl iPb-qadMil cipiQty Assiy 
Palane^a (2010) 
Iqectabie (DMPA-depot 
n>e(k(nypiogedcn»e accUte), Oid piU-
ethmyl eatraJol and deaogestrel 
Senmihp<fc Elevate lipid level in cral piit users and low 
HDL and high LDL level m DMFA usas 
Berenson "t J, UOW | 
Oral CTotrioetifcves Senm proteui and cfaoleattrol HJijief seram proteui, inaetsed dwleslerol levtis Ohsesan >»< g. (2002 
(20")' Loir dOK contnccpfava (etlan^lefiradcd) 
combmed with progestm component 
Aeao«eat or itriMBWcnooe 
Effect on deep venous diromboas 
and aitenal by lipid abnonnalitacs 
Deep venous lhrombo'3'!: in user: (aitena! 
thrombosis mcreases) 
Tzanksna 
Biphase lofenunal taUeta (nargestrd+ 
etfamyleHradol) 
Senm bpida and Mood preaaure Total hpid mcreases reduced Uood pressure levd Emokp«e»'(a/ (2010) 
Edmyiearadoi andprogeann Blood presaure and Senim teal 
hpida 
Higher systolic blood pressure and higher level 
of aeram total hpids 
Nawrot-' 2. (2U0J) 
Low dose cral ccntraceptave (ethmyl 
eatraJol/geatodene) 
Lipid levd and Blood pressure Nonnal level of lipids, Nonnal Mood pressure Qinbelac ai (2007) 
Mcnophiac pill< ttlbaM edndiol) Blood (ample (Total plaama cof«»l 
was measured with a 
radiaunmunouaiQr) and first sahva 
sample (Baaal fiee Cortisol level) 
Basal free Cortisol levd mcreases No effect on 
corhsollevd 
Kuschtmum et al (1999) 
Combined onri contraceptive (estrogen 
eflmyleah^dlol+progeatowen) 
Senm Lipids and bpoprctetns Senan hpitfe is higher Abdd Banye ai (2011) 
Lyndlcl pill (lynoealienol andprogeshn) 
Oral cxMiiaxptive ^cntsconibinafaan 
type (ProKcatowP-tEatun'Oi) 
SOOT levds (aenan glutamic 
oxaloacetic tranaammaae) 
Increase m SOOT (senim glutamic oxaloacetic 
transaimnaae) 
Nonnyl (1 mg of ooretfaui(kt«e 480 pg 
ofmcstranol'l 
Concenlrafaon of plasma 
ascoifaic aad m leukocytes 
Decrease plaana ascoitic aad 
Vitamm levd and hpid levds m 
scnsn 
Oral oonhaceptive 
Decrease m senim vitsnm 
BlZ, lipid Ictclm scrum hirfict 
Serum hpids Inaease level of saum hpids 
Stdl (1967) 
McLeroy and Schendd 
11973; 
Smith el a( (1975) 
Kannd (1979) 
Oral conhacepbve pll (norethmct-ane-^  
meatranrt) 
Senim hpidE Higher In-ds (^total lipids 
Ccotraccptive pill (Ievonorgeatiel+ 
ettmylestiadol) 
Serum Upids Deaease e^nlm lipid:> 
Contraceptive pill Plasma vitamms (A, E, c | plaana 
biglycendes and cholesterol, 
leukocytes 
Increase level ot vitanin, plasma, tnglycendes, 
diolesterol, leukocytes that makes the nsk of 
myocariial miection 
Heanefcen" 
Dt^ iiacket " a (19oij 
veung(iv'6) 
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Table 1 Caotmue 
Oral ContnctDtive 
Noretbmdtme, Ottho-Novum (l/3i 
and 777), ediynodiol dacetate 
Cambued oral contracqitive 
eslrogai-)frogestu(desogeslrd. 
ievoncrxestrd and Doretiiistercme) 
Combined pills (etbuiytMtndlol) 
Oral contraceptave pill 
Levonorgeslrel (90 fig), etbuiyl eslradol 
(20 W() 
Moaophaac oral ccotractptive 
(levooorgestrel (100 fig) 
1 oliiovicslradiai 2u m> 
Oflho-Novum 7/7/7, TYiphaal 
(cambuiataoa of Nordliindrone, ethinyl 
eslradol), 
Cypniterane acetate. Lipid 
metabdism, binutism -l-dbuiyleatradol 
DesoKestrd-t^ ttunvl eslradol 
Mifepnstcoe (contraceptive pill) 
Etbmylcgtndid and 
cUonnadnooe acetate 
Dqwt medroocyprogesterone Oral 
conirtceplive ptU (20 UK). 
Ural confracepdve (edunyl eslradoi-i-
norgestunate) Contraceptive patdi 
(etiiinjiesliadloi-fnofelgeslroiiui) 
Elfainylegtiadol+progestui 
Oral contraceptive 
(estrogen), DMPA(progestin) 
Oral contraceptive (30 fig ethmyl 
ealradicl+2 mg dioiogegt) 
Mircette (desogestrd/etliinyt eslradiai) 
Oni contraceptive Fill 
Parameter Studed 
Lipoproteins and Serum lipids 
Histopalhology 
Bone markers, Scrun biodionstiy, 
Bone mineral measurement 
Senin levels of lipid-aoluble 
anHondants 
Demograptac data 
Foilide dameteii and serum 
progesterone and 17 P-estndd 
Serum conccntntion of ethmyl estradiol 
by Ridoimmunoissay 
Lipid mctaboliam mcreased. 
of adolescents with polycyshc 
ovarv syndxime (PCOS) 
Biocfaeimcal parameter (scrum allcalme 
phosphatase and amim glutamyl 
pyruvate transaminase) 
Assesantnt of ov>i an fimdioa. 
tfaidcoets of eadometnum, cervical 
reaction sex, hormone levd and 
overall tdcrabibty 
Menstrual symptoms and Physiologic 
symptoms 
Bo(^ Mass Index (BMI) and serum 
andogco levels 
Pdvic pam, bleedog, headaches. 
breast tenderness 
Demographic <Wa fam, serum 
tettosterone and estradiol levd 
Survey based SbK^ 
Serum lipids, caitiofaydate 
metabdian, endocnnc parameters 
Standard questiconane was used 
to record desoiplive diaractenstacs 
andmedcal and reproductive history 
Concluaoo 
Higher lipoprctem, high Serum hpids 
Risk of endometnal cancer is decreased 
Decreased bone forauticn, scrum albumm is 
lower m oral contraceptive 
users Noimal bone mmeral 
Lowa levd of serum levds of hpid 
soluble aitfioradants 
Use of this compoataon does not dday 
the return to fotihty 
Suppfe&>ioa of ovanan activity m u&cr> 
Scrum concenlrMion of etbmylestradicl mcreascs 
Lipid metabdian mcreased, deaease hirsuhan 
Increase biocheimcal [>aramctas 
(scrum alkahne phosphatase and 
pyruvate transaminase), serum glutamyl 
Inhibihon of ovulataon and m&vourable 
condibon for fcrtUizAon, pregnancy 
No adverse effects 
IIM coHracepnve patch had an ettect 
comparable, to the OC on several key andogemc 
potenbal as a therapeutic agent for dsorders of 
andxiscn excess 
Pdvic pam, faleedng and breast 
tenderness Aown, headadies problem, breaa 
tenderness shown 
Oral ocotraceptives have low level of testosterone 
compared to DMPA and high level of eslradol 
Sbght delay m r^ainmg fertility 
afier the use of this oral contraceptave. 
Increase serum lipds, no 
chaises in caitxiliydate metaboban, 
effect on endoome parameter 
Liver caranoma found m 
oral coitfraccptave users 
Author 
Walsh and Sacks (1993) 
Wadcrpasseta/ (1999) 
Qamaoetal (1995) 
Pdanefoi (2006) 
Bmbtrtetal (2009) 
Coney and DdContc 
(1999) 
Smi^ky and Fasifiale (1998) 
Utstonkasetal (2002) 
Agarwde«a/ (2009) 
Spam eta! (2010) 
Berenson e; 12/ (2008) 
White ctoJ (2005) 
Sulakefoi (2000) 
ScfaafBreta/ (2010) 
Wicgratzrfa/ (2006) 
Beiga (1998) 
Pakncreta; (1989) 
CONCLUSION 
The studies perfortn on Oral contraceptive users 
clearly shows the marked effects on enzymes, 
carbohydrates and serum lipids High level of serum lipid 
invites many problems to the contraceptive users i e , 
cardiovascular risk by increase m the cholesterol level but 
the full impact of oral contraceptive on cardiovascular nsk 
factors may not be fully concluded from the short 
duTdtioii of studies done so fdr Tlie durdlion of oral 
contracejAive also have importance in stucfying the effect 
amoi^ the women We must leam the correct durahcwi of 
usage,'dosage more wisely and keep their user aware 
about the affect of oral contraceptive The efforts should 
continued to produce safer cral contraceptive for tlie 
users 
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Abstract Synthetic progestins and estrogens have been reported to be toxic in vanous expenmen 
tal models Their prolonged use has been reported to induce cancer in humans In the present study 
the effects of oral contraceptives were studied among users using chromosomal aberrations, sister 
chromatid exchanges and DNA damage as a parameter, in cultured human peripheral blood lym-
phocytes The study was performed on 25 women (users) and 25 age match controls No significant 
difference was observed in chromosomal aberrations and DNA damage A significant increase was 
observed in sister chromatid exchanges (SCEs) Ceil among users The results obtained and the nsic 
of oral contraceptives (OCs) genotoxicity have been discussed 
© 2012 Am Shams University Production and hosting by Elsevier B V All rights reserved 
1. Introduction 
Oral contraceptives are tiie combination of estrogen and 
progesterone They are used to treat vanous liormonal 
disturbances, premenstrual syndrome and ovarian cysts [1] 
Tiie composition of pills vanes from country to country due 
to the responsiveness variation from individual to individual 
or one population to another [2] Earlier reports suggest the 
genotoxic effects of synthetic progestins in cultured human 
Corresponding author 
E-mail address yasirhdsansiddique'o.redifrmailcom (Y H Siddique) 
Peer review under responsibility of Am Shams University 
peripheral blood lymphocytes [3 7] In these studies the geno-
toxic eiTects were observed at very lugh doses and, the reactive 
oxygen species (ROS) was suggested as a causative agent for 
the genotoxic damage [8,9] The conversion of estrogen into 
catechol estrogens and quinines, via redox reactions causes 
oxidative damage to DNA [i 10] There are l>oth positive as 
well as negative reports regarding the genotoxic effects of 
estrogens and synthetic progestins [11 13] In the present study 
an attempt has t)een made to investigate the possible genotoxic 
effects among oral contraceptives (OCs) users (females) by 
using chromosomal aberrations, sister chromatid exchanges 
and DNA damage as a parameter 
1110-8630 © 2012 Ain Shams University Production and hosting by Elsevier B V All nghts reserved 
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2. Subjects and methods 
2 / Chemicals 
RPMI 1640, fetal calf serum, phytohaemdgglutinin-M, antibi-
otic antimytotit mixture (Invitrogen), 5-bromo-2-deoxyun-
dme, Giemsa stain (Merck, India), Tns HCl, EDTA, Triton-
X, Tnchloro acetic acid and diphenylamine, colchicine (SRL, 
India) 
2 2 Human lymphocy te culture 
A sample of hepannized venous blood was obtained from 25 
women taking an OCs preparation containing levonorgestrel 
and ethinylestradiol as a content for 12 months as a means of 
contraception following their first pregnancy Age matched 
healthy 25 controls were evaluated along with the above sub-
jects A written informed consent was obtained from all sub-
jects Tlie mean age of 25 women using OCs was 28 5 years 
and of the 25 controls was 27 5 years Individuals answered a 
questionnaire relating to lifestyle factors The OC users were 
not having any other addictions such as smoking, alcohol 
drinking etc nor have any history of disease Briefly, hepann-
ized blood sample (0 5 ml), was obtained from each female 
and was placed in a stenle cultured tube containing 7 m] of 
RPMI 1640 medium, supplemented with fetal calf serum 
(1 0 ml), antibiotic-antimycotic mixture (1 0 ml) and phytohae-
magglutinin-M (0 1 ml) The culture tubes were placed in the 
incubator at 37 °C for 48 h [14] 
2 3 Chromosomal aberration analvsis 
After 47 h, an amount of 0 2 ml of colchicine (0 2 ng/ml) was 
added to the culture tubes Cells were centrifuged at 800 g for 
10 min TTie supernatant was removed and 8 ml of pre 
warmed (37 °C) 0 075 M KCI (hypotonic solution) was 
added Cells were re-suspended and incubated at 37 °C for 
15 mm TTie supernatant was removed by centnfugation, at 
800 g for lOmin, and subsequently 5 ml of chilled fixative 
(methanol glacial acetic acid, 3 I) was added The hxative 
was removed by centnfugation and the procedure was re-
peated twice The cells were stained in 3% Giemsa solution 
in phosphate buffer (pH 6 8) for 15min About, 300 meta-
phases were examined for the occurrence of different types 
of abnormality Critena to classify different types of aberra-
tion were in accordance with the recommendation of Envi-
ronment Health Criteria 48 for Environment Monitonng of 
Human Population [15] 
2 4 Sister chromatid exchanges 
For sister chromatid exchange analysis, bromo deoxyuridine 
(lOng/ml) was added at the beginning of the culture and 
the mitotic arrest was attempted, 1 h pnor to harvesting by 
adding 0 2 ml of colchicine (0 2 ng/ml) Hypotonic treatment 
and fixation were performed as descnbed for chromosomal 
aberration analysis The sister chromatid average was taken 
from an analysis of metaphase during second cycle of divi-
sion A total of 25 well spread metaphases were scored per 
individual [16] 
Genoloxic damage in cultured human f)criphcral blood lymphocytes of oral contraceptive uscrb < 0 i 
2 5 Quantitative assavjor DMA Jragmentation '6 Statiitual analvsis 
Quantitative assay for DNA fragmentation was performed 
according to the protocol of Burton [17] After mcubation of 
48 h, the cell suspension containing 1-10 x 10* cells m a 1 ml 
volume was prepared for each donor About, 0 8 ml of cell sus-
pension was transferred to a micro centnfuge tube and 0 7 ml 
of icc cold lysis buffer (5 mM Tns CI, pH 8 0 20 mM EDTA/ 
0 5% (v/v Tnton X-lOO) was added The tubes were vortexed 
and allowed to lyse for 30 mm at 4 °C The tubes were centri-
fuged for 15 mm at 15,000 g (4 °C) and the supernatant was 
transferred to a labeled conical glass tube About 0 65 ml of 
5% tnchloroacetic aad (TCA) was added to the pellet in a mi-
cro centnfuge tube and 1 5 ml of 10% TCA to the sample in a 
labeled glass tube The sample was precipitated overnight at 
4 °C The tubes were centnfuged for 10 min at 2500 g at room 
temperature and the supernatant was removed and about 
0 65 ml of 5% TCA was added to the pellet The tubes were 
boiled for 15 mm at 100 °C in a water bath After coohng 
down to room temperature the sample was centnfuged at 
2500 g for 5 mm About 0 5 ml of each supernatant (from both 
glass and micro centnfuge tubes) was added to the labeled 
glass tube About, 1 ml of diphenylamine reagent was added 
to each tube and was incubated for 4 h at 37 °C [18] Finally 
the absorbances were noted at 600 nm in a spectrophotometer 
and the results were expressed in the percentage of DNA frag-
mented as follows 
%Fragmented DNA = 
absorbance of supernatant 
dbsorbance of supernatant + pellet 
Student's / test was used for the analysis ol data obtained for 
chromosomal aberrations and sister chromatia excnanges and 
X' (Chi-square) was applied for the analysis ol DNA damage 
3. Results and discussion 
Tlie frequency of cells with aberration in OC users was almost 
similar to their age matched controls Gaps and breaks of chro 
mosome as well as chromatid were observed but dicentric ex 
changes and rearrangements were not observed The mean 
values obtained were not statistically significant (Tahle I) A 
significant difference {P > 0 005) in the number of SCEs cell 
was observed between OC users (3 9 J- 0 076) and their agt 
matched control (2 62 ± 0 068) (Table 2) The mean value for 
the DNA damage was (0 1172 ± 0 0020) in OC users and 
(0 1148 ± 0 0025) in controls The values were not staiislicallv 
significant (Table 3) The results of the present study suggest 
that the OC users have significantly higher Irequencies of 
SCEs/cell, but the CAs and DNA damage wert not significant 
An increase in the frequencies of SCEs and CAs has been rt 
ported dunng pregnancy [19 20] The concentration ot the 
estrogens is increased dunng pregnancy, which may be the pos 
sible reason of an increase in SCEs [21] Earlier studies per 
formed on the genotoxic potential of steroids have shown to 
cause chromosomal damage, induction of SCEs and formation 
of endogenous adducts [7 22 24] The results of the present 
study show that the OCs are not potent in inducing DNA 
Table 2 Distribution of Sister chromatid exchanges (SCEs) 
among women using oral contraceptives (OCs) 
Subjects SCE per cell 
Table 3 Estimation of DNA damage among oral contracep-
tives (OCs) users and non-users 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Mean ± SE 
OC users 
4 2 
41 
4 3 
3 9 
35 
36 
37 
3 3 
3 7 
38 
41 
4 0 
32 
32 
33 
4 2 
4 1 
4 3 
4 4 
4 0 
4 3 
42 
41 
39 
4 4 
3 91 ± 0 076* 
Control 
2 3 
25 
2 9 
27 
2 4 
23 
2 6 
31 
22 
2 3 
2 4 
25 
32 
2 9 
28 
27 
32 
2 2 
28 
2 7 
2 4 
2 3 
28 
21 
33 
2 62 ± 0 068 
Subjects 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Mean ± SE 
OC users 
0 11 
0 12 
0 12 
0 13 
0 12 
0 10 
Oil 
0 13 
0 14 
0 12 
Oil 
0 10 
Oil 
0 12 
Oil 
0 13 
0 13 
0 12 
0 12 
0 12 
Oil 
0 12 
Oil 
0 10 
0 12 
0 1172 ± 0 0020 
Control 
0 10 
0 II 
0 12 
0 II 
0 12 
0 13 
0 13 
0 12 
0 11 
009 
0 08 
0 II 
0 12 
0 II 
0 12 
0 13 
0 11 
0 12 
0 12 
0 13 
0 12 
0 II 
0 10 
0 12 
0 n 
0 1148 ± 0 00252 
P > 0 005 NS (Non significant) 
F Na/ ei al 
damage/chromosomal aberrations, but are able to increase the 
number of SCEs/cell The study performed by Bin et al [25] also 
showed the mcrease m SCEs/Cell in OC users The SCEs are the 
cytological manifestation of interchanges between DNA repli-
cation products at apparently homologous loci It is more sen-
sitive mdicator of genotoxic effects than structural aberrations 
[26,27] The induction of SCE is also correlated with the induc-
tion of cancer [28] Besides various reports on the genotoxicity 
of steroids some of the progestogens have been studied in short 
and long term toxicology studies in rodents and dogs or mon-
keys for their carcinogenic activity, no significant or unusual 
toxicities were reported [29] In some cases the oral contracep-
tives have also been suggested to be having a role in prevent-
ing ovarian cancer by both suppressing ovulation and altenng 
the timior promoting milieu [30] The results obtained in the 
present study are contrary to the studies performed by other 
workers [13,31,32] This may be due to the new hormonal 
formulations and preparations developed in an attempt to re-
duce the adverse effects of OCs, such as the reduction in the 
estrogen content Estrogen such as ethinylestradiol, in the li-
ver undergoes aromatic hydroxylation and the product, 4-
hydroxyestrone, 3,4-dihydroxy 1,3,5 (10)-oestratien-17-one 
(4-OHE) IS carcinogenic in male Syrian golden hamster kid-
ney tumor model [33,34] The genotoxic potential of steroids 
IS determined by the metabolic conditions in the test system 
and the human body The extrapolation from the expenmen-
tal data to humans is not only difficult but also complex The 
most of the studies conducted for genotoxic potential of ste-
roids involve the concentration in microgram per ml range 
whcred!> the therapeutic plasma concentration ranges from 
nanogram or picogram per ml [7] The present study was con-
ducted on the women taking OCs for one year and the in-
crease in SCEs may be due to the variable hormonal profile 
among them Further, the occupation and work place, poly-
morphic metabolizing genes and efficiency of DNA repair can 
also affect the resjwnse against OCs 
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Lipid Profile of Women Using Oral Contraceptive Pills 
'F N a z , ' S J y o t i , ^ A k h t a r , ' M A f z a l a n d ' Y H Siddique 
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'Department of Obstelricb and Gynecology, J N Medical College, Ahgarh Mubhm Univcrbity 
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Abstract: Oral Contraceptives (OCs) are the most popular type of birth control pills The study was designed 
to examine tlie biochemical charges which occui due to tlie use of oral contiaceptive piUh \,OC^i Tlie ^tudv Wd^  
based on the questionnaire for having the information of any reproductive history fasting, age, health, nature 
of menstrual cycle, bleedu^, disease etc and blood profilir^ for biochemical anaij-sis of the women mcluaes 
High Density Lipoprotem Cholesterol (HDL-C), Low Daisity Lipoprotem Cholesterol (LDL-C), Total Cholesterol 
(^ TC; and Tnglycendes (TG^ Lipid profiling was earned out by using a commerciall) available diagnostic test 
kits SPSS was used to analyze the data The results showed statistically significant differenceb among 
useis of OCs compared to non-users Total cholesterol (242 92i2 842 mg dL" ), HDL-C (58 65± 1 098 mg dL » 
LDL-C (115 84±1 266 mg dL~') and tnglycaides (105 56tfc2 341 mg dL"') were significantly higher compared to 
the Non-usere (Total cholesterol 218 4S^1 762, HDL-C 48 17ztO 543, LDL-C 100 32±0 951 and tnglycerideb 
8377 i2 299iiigdL~') The result suggests that OCs mcrease the level ofHigh Density Lipoprotem Cholesterol 
(HDL-C), Low Density Lipoprotem Cholesterol (LDL-C), lotal Cholesterol ( IC) and Inglycendes ( IG) 
Key words: Oral cQutracepUves, liealtliy womeii, biochemical pdrdiueterb 
INTRODUCTION reported (Thorvaldsen et al, 1995 Vessey et at 1984 
WHO, 1996; and other studies showed diat orai 
From the last few decades, world is facing the most contraceptives also mcreases the nsk for venous 
senous problem that is population explosion Uiiomboembohbm (Famiei and Ldwieiiboii, 1998, Wei^-, 
Contraception method IS used worldwide for over birth 1999, Westhoff, 1998, Rosing and Tans, 1999 
control or unwanted pregnancies Many workers have Kemmeren ef a / , 2001) The relationship betweer. ural 
si^gested that the use of contraceptives is beneficial but contraceptive users and the nsk for breeist cancer 
also have some side effects too The researchers believe remains controversial Moit itudie!> ^uggesti, no 
that the widespread use of hormonal contraceptive oversdl nsk or a shght mcreased nsk of breast cancer m 
provides an opportunity for assessing the influence of women using oral contraceptiv es (^Anonymous 1986 
estrogens and progesterone on vanous biochemical Marchbanks et al, 2002, Bnnton et al, \ 998 
parameters among users Synthetic progesUns not only Hankinson et al, 1997; It has been reported thai the 
have genotoKic potertial (Siddique and Afzal, 2(X)4,2(X)5a, serum total cholesterol is significantly higher among oral 
Siddiqueefa/,2(XJ5a,b, 2006a, b) but are also vulnerable contraceptive users as conpared to non users 
to vanous types of cancer (Siddique and Afzal, 2(X)8, (Nawrot et al, 2003) The mocfe of action dep>ends upon 
Siddique and Afzal, 2005b) It was found that the bone the formulaticm of pills The pills possibly mliibits 
formation was sigmficantly decreased m women taking ovulabon by the fcxmation of pituitary luteinizing 
oral contraceptive pdls (Gamero et al, 1995) Some hormone that renders the cervical mucus hostile to sf»mi 
remarkable findu^s are well documented by woikers penetrabon The oral contraceptive pdls are the 
which showed that oral contraceptives are mvolved m ccmibination of different concentrations of estrogen and 
many diseases such as, myocardiac infracbon and prc^estin. In our present study the composition of the 
carcmogemcity (,Obisesan ef a / , 2002, Tzankova e/^  a2 , oral contraceptive taken by the women was Etiiinyi 
2010, Naz et al, 2012) An mcrease m the nsk for ischemic Estradiol (EEj) (0 03 mg) and Levoncogestrel (0 1 5 mg) 
stroke m women takii^ oral contraceptives has been In the present study an attempt lias been luaut. (u 
Corresponding Antfaor Y H Siddique, Human Genetics and Toxicdt^'Laboratory', Section of Genebes 
Department of Zoc4ogy, Aligarh Mushm Uraversity, Aligarh-202002 (U P), India 
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investigate the piossible effects of Oral Contraceptives 
(OCs) among users on High Density Lipqsrotein 
Cholesterol (HDL-C), Low Density Lipoprotein 
Cholesterol (LDL-C), Total Qiolesterol (TC) and 
Triglycerides (TG). 
MATERIALS AND METHODS 
Sample size: The subjects for the study were married 
women of low income group to a total of 100 participants 
from Malkhan Singh Hospital and Jawahar lal Nehru 
medical college of Aligarh city, who were of 21 to 40 years 
of age, from which 55 women were taking combined oral 
contraceptives preferring after 8-10 days of withdrawl 
paiod and 45 non-users healthy married women who were 
not takir^ any oral contraceptive. A random sampling 
were performed and the women taking the oral 
contraceptive continuous for the three months were 
included for the comparison to non-users. A written 
consent was obtained from the subjects for taking their 
blood samples. The detailed questionnaire included some 
issues about fasting, age, health history, nature of 
menstrual cycle, bleedir^, disease, etc. 
BkMid sampling and processing: In morning as overnight 
fasting of user and non-user WOTnen, about 4 mL blood 
was collected in vacutainer tube with clot activator from 
each women in study sample. The serum samples were 
obtained by centrifugation at 3000 rpm for 15 min and the 
sera were stored at -20^C and analyzed within three days. 
Blood parameters analysis: The analysis of lipid profile of 
High-Density Lipoprotein (HDL-C), Low-Density 
Lipoprotein LDL-C, cholesterol and triglycerides were 
carried out using a commercially available diagnostic 
system test kits (Crest Biosys terns kits, India). 
Statistical analysis: The obtained data were analyzed by 
using a software statistical package SPSS version 16.0. 
Students t- test was also used to differentiate between 
two numerical data. 
RESULTS AND DISCUSSION 
The results of the present study suggest that the oral 
contraceptive users have higher level of total Cholesterol, 
HDL-C, LDL-C and triglycerides as compared to non-
users. As shown in the Table 1, the mean values of 
Cholesterol (242.92i2.842),HDL-C(58.65±1.098), LDL-C 
(115.84±1.266) andtriglycendes (105.56±2.341 mg dL"') 
were significantly higher among users as compared to the 
non-usere (total Cholesterol 218.49±1.762, HDL-C 
48.17±0.543, LDL-C 100.32iO.951 and triglycendes 
83.77i2.299mg dL^') (Fig. 1). 
It has been observed that the LDL-C and HDL-C 
UKrease is prcme to have stroke and myocardial 
infarction in women taking oral contraceptives 
(Wynn et al, 1966). The present study supports tlie 
earlier studies on lipid profiles on cholesterol 
(Emd^jae et al, 2010, Abdel-Bany etal, 201V). Elevated 
serum levels of lipids are probably the most important 
biochemical risk factors for atherosclerosis. In the liver 
friglyceride synthesis is enhanced by esfrogen and 
inhibited by androgen and these triglycerides are partly 
broight into the circulation as low-density lipoproteins. 
When a contraceptive pill containing an estrogen and a 
progestogen is introduced, the resultant effect is not 
predictable. The clinical significance of this observation 
is supported by the fact that atherosclerosis begins early 
in life and is accelerated in the presence of high 
cholesterol and serum triglycerides (Newman etal, 1991). 
Contraceptive steroids having a combination of an 
estrogen and progestin or only progestm are effective and 
reva^ibly regulate fertility. Combined oral ccxitraceptives 
afTects a variety of metabolic factors includir^ hemostatic 
variables and esfrogen-sensitive Uver proteins and these 
effects can be modulated by the type of estrogen and 
progestin in a given canbination (Sitruk-Ware and Nath, 
2011). The estrogen component of OCs has been reported 
to increase the production of Very Low Density 
Lipop-otein (VTDL) aixi High Density Lipop-otein 
(HDL) but reduce the level of low density 
lipoprotein (Sitruk-Ware, 2006). Tlie reducticm in the 
doses of Levonoigestrel/ethinyl estradiol containing 
contraceptives from 30-20 ng (EE) and that of 150-100 )ig 
TAIcl: Lipid profile 
Lipid profile (ms dL 
Cholesterol 
HDL-C 
LIX.-C 
Trialvcerides 
of oral contraceptive (OC) users 
'2L- OC users (n = 55) 
24292±1842' 
58.65±L09ff 
115.»4±1.26e 
105.5<it2i41' 
and non-users women 
Non-users (n = 45) 
2ia49±1.762 
48.17i0.543 
100.32t0.951 
83.77±1299 
Values are as Mean^SE, 'p<0.05 significant with respect to non-users 
3001 
250 
200 
150 
too 
50 
0 
nUsers 
oNon useres 
Cholesterol HDl.-C LDL-C Triglycerides 
Fig. 1; Lipid profile of oral contiaceptive users and 
non-users 
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(levonorgestrel) resulted in tiie less adverse effect on 
the lipid profile and have been suggested to lower the 
incidence of thrombosis as compared to other EE based 
contraceptives (Skouby et al, 2005; OCs containing 
levonorgestrel was associated with an almost four times 
higher nsk of venous thrombosis as compared to non-
usere (VanHylckama Vlieg efa/,2009) The intake of 
100 Jig levonorgestrel with 20 \i% ethinyl estradiol to 28 
women whom were at the nsk of pregnancy shows a httle 
change in hpid profile as compared to higher dose oral 
contraceptive preparation (Young and DelConte, 1999) 
Despate the changes m lipid profile among users of higher 
dose oral contraceptive stents, there is little and no effect 
on the loi^ term nsk artherogemc cardiovascular disease 
(Stampfer et al, 1990) The status of elevated seiiim 
triglycende level may be an mdependent predictor of 
coronary heart disease as ethutyl estradiol mcreases 
heptatic secretion of triglyceride nch lipoprotem 
(Avins etal,l989; Schaefer etal,\983) The prc^estm 
component of the OC may oppose this increase The 
mjectable oral contraceptives have also been reported to 
increase the levels of tnglycendes, total cholesterol, High 
Density Lqxjprotem (HDL) cholesterol in the serum 
(Godslande/a/,1990) 
CONCLUSION 
The lipid profile depends on the brand of OCs or 
duration of their use The users m our present stu<fy were 
taking OCs of ethmyl estradiol (0 03 |ug), levonorgestrel 
(0 5 Jig) The increase m the Iqnd profile may be attnbuted 
to their responsiveness to the dn^ However, the long 
term effects were not taken mto account in the present 
stucfy, but still there is a need of a detailed study taking 
the various life style factors into the consideration 
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